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SUMMARY 
   
 
SUMMARY 
Pulmonary delivery is considered an attractive route of drug 
administration for chemotherapeutic agents, with the advantages of 
high drug concentrations locally and low side effects systemically. 
However, fast clearance mechanisms result in short residence times 
of small molecule drugs in the lung. Moreover, the local toxicity 
induced by antineoplastic drugs is considered a major obstacle for the 
application of inhaled chemotherapy in the clinic.  
In this study, we aimed at developing polyethylene glycol-paclitaxel 
(PEG-PTX) conjugates in order to retain paclitaxel within the lung, 
achieve its sustained release locally and reduce its toxicity to the lung. 
The conjugates were expected to present increased efficacy in the 
treatment of lung cancer, as compared to the quickly-cleared native 
drug. 
Two structures of PEG-PTX conjugates with PEG molecular weights 
of 6 kDa and 20 kDa were synthesized. One structure was synthesized 
with azide linker using “click” chemistry and the other was synthesized 
with a succinic spacer. Conjugation to PEG improved the solubility of 
paclitaxel by up to four orders of magnitude. The conjugates showed 
good stability in phosphate buffer saline and in bronchoalveolar lavage 
at both molecular weights, but hydrolyzed quickly in mouse serum. 
The conjugates showed cytotoxicity to B16-F10 melanoma cells and 
LL/2 Lewis lung cancer cells but less than free paclitaxel or Taxol, the 
commercial paclitaxel formulation. The conjugates synthesized by 
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“click” chemistry were chosen for the evaluation in vivo because they 
were more stable in different media than the succinic conjugates.  
Results in vivo showed that the conjugates increased the maximal 
tolerated doses of paclitaxel by up to100-fold compared with Taxol 
following intratracheal instillation in healthy C57Bl/6 mice. The anti-
tumor efficacy was assessed in the Lewis lung carcinoma cell-induced 
lung cancer murine model. It was enhanced significantly by delivering 
PEG-PTX conjugates to the lung, compared with Taxol delivered either 
intratracheally or intravenously. PEG-PTX 20 kDa (20 mg/kg PTX 
equivalent) showed equivalent anti-tumor efficacy as PEG-PTX 6 kDa 
delivered at a higher dose (50 mg/kg PTX equivalent). PEG-PTX 
conjugates increased biochemical and cellular markers of 
inflammation in the lung at their maximal tolerated doses. However, 
decreasing PEG-PTX 6k dose lowered local toxicity. Delivery of PEG-
PTX conjugates to the lungs resulted in prolonged retention of the 
conjugate and sustained paclitaxel release in the lung over more than 
48h. This study demonstrated that PEGylation offers a potential drug 
delivery system for inhaled chemotherapy with improved anti-tumor 
efficacy and reduced local toxicity.  
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千里之行，始于足下。 
A journey of a thousand miles begins with a single step. 
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1. Lung cancer and current therapies 
Lung cancer is the most common cancer worldwide and causes a 
large number of death 1.4 million per year (1). More than half a million 
patients are diagnosed with lung cancer each year and about 80% is 
non-small cell lung cancer (NSCLC), including adenocarcinomas, 
large cell carcinomas, and squamous cell carcinomas (2). Primary 
lung cancers mainly originate from lung epithelial cells and result from 
smoking and exposure to contaminants. Metastasis of other cancers 
(e.g., breast and prostate cancer) are also frequently found in the 
lungs (3). Most patients are diagnosed with lung cancer when the 
cancer has become locally advanced or spread distantly. The typical 
treatments for lung cancer are surgical resection, radiotherapy and 
chemotherapy.  
1.1 Surgical resection  
Surgical resection is commonly regarded as the most effective 
treatment for early stage NSCLC limited to the lung and surrounding 
glands with tumor cells. Most surgeries have shown five-year survival 
rate from 55% to 72% in patients with localized stage I NSCLC, and 
29% to 51 for patients with stage II NSCLC (4). But only about 20% of 
tumors are suitable for resection (5). Moreover, there is no convincing 
evidence to certify that surgeries improve survival of patients 
compared with other treatments, for instance, radiotherapy or 
chemotherapy.  
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If a limited resection is performed to individuals with localized cancers, 
the chance of local recurrence will increase. A more extensive 
resection could decrease this risk. Chemotherapy sometimes is 
combined with surgery. However, chemotherapy followed by surgery 
showed no better effect than chemotherapy followed by radical 
radiotherapy in terms of overall survival (4).  
1.2 Radiotherapy 
Patients who are not suitable for surgical resection due to 
comorbidities (e.g., heart disease) are treated with conventional 
radiotherapy for early stage lung cancer. Results are not ideal because 
conventional radiotherapy is not effective to 60-70% of patients with 
primary lung tumor (6). Generally, the combination of cytotoxic 
chemotherapy and radiotherapy could improve efficacy compared with 
radiotherapy alone. Recent research results from clinical trials using 
advanced irradiation delivery techniques have demonstrated that 
patients treated with these modified therapies together with cisplatin-
based chemotherapy have a superior long-term survival compared 
with those who were only treated with radiotherapy or chemotherapy 
(7, 8). However, the combination treatment is usually accompanied 
with increased toxicity in the radiation field. More hematological 
toxicity is often observed in patients receiving combination treatments 
(9). 
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1.3 Chemotherapy 
Chemotherapy has been widely used to treat non-small cell lung 
cancer. It can be administered as single treatment or combined with 
surgery or radiotherapy in radical or palliative treatment. 
Chemotherapy after radiotherapy or surgery can help patients live 
longer. Combinations of different anti-cancer drugs in chemotherapy 
tend to work better than a single drug. Cisplatin and carboplatin play 
an important role in the treatment of both small cell lung cancer and 
non-small cell lung cancer, and the combination with  gemcitabine, 
etoposide, vinorelbine, paclitaxel (Taxol) (Fig. 1), docetaxel (Taxotere) 
or doxorubicin are frequently used in treating non-small cell lung 
cancer (2, 10, 11). 
 
Fig. 1 Molecule structure and 3-D structure of paclitaxel. 
Generally, chemotherapy prolongs the survival of patients with 
advanced NSCLC by 3 to 6 months compared with best supportive 
care (12). Combination of platinum with other chemotherapeutics can 
improve survival compared with best supportive care or single 
treatment of cisplatin. However, there is only 2-month extension of 
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median survival time. Survival at 1 year only has an increased 
probability of 10% to 20%. The addition of bevacizumab, an 
angiogenesis inhibitor, to platinum treatment has prolonged survival 
time of 2 months compared with chemotherapy alone (13). The 
unsatisfactory clinical efficacy of chemotherapy can be attributed to 
the low local drug concentration in the lung tumor and the severe dose-
limiting side effects.  
It is reviewed in (14) that the inefficient drug penetration from blood 
vessels in solid tumors leads to unsatisfactory anti-tumor effectiveness. 
The limited drug penetration is illustrated in Fig. 2. The oxygen, 
nutrients and energy, and drug concentration were in decreased 
gradients from the blood vessel to the tumor region.  
 
Fig. 2 Illustration of the gradients in oxygen, nutrients and energy, and drug 
concentration in solid tumor cells. ECM, extracellular matrix (adapted from 
(14) ).  
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Most chemotherapy is administered by the systemic route, so side 
effects are severe. The most common adverse drug reactions are 
induced by the effects of chemotherapeutic agents on rapidly dividing 
cells. Therefore, hair loss, white and red blood cell-count lowering may 
occur. Mouth sores and nausea may also happen (15). In addition to 
these common drug reactions, peripheral neurotoxicity is a dose-
limiting and disabling side effect of many frequently used anti-cancer 
agents, in particular, paclitaxel, cisplatin, vincristine, oxaliplatin, and 
docetaxel. Specifically, systemic administration of paclitaxel usually 
induces myelosuppression and hyper sensibility reactions in addition 
to peripheral neuropathy. 
Many anticancer agents have unsatisfactory pharmaceutical and 
pharmacological attributes, i.e., poorly water solubility, instability, 
irritating feature or fast metabolism. Different drug delivery systems 
have been developed for chemotherapeutics including liposomes, 
nanoparticles, polymeric micelles, and polymer-drug conjugates. 
Liposomal doxorubicin (Doxil), and nanoparticle albumin-bound 
paclitaxel (Abraxane) are two widely used formulations for cancer 
therapy now on the market. Doxil was the first nanoscale delivery 
system approved in US. It is approved for the treatment of AIDS-
related Kaposi’s sarcoma in the year of 1995. Then it was approved 
for treatment of ovarian cancer and multiple myeloma in US in the year 
of 1999 and 2007, respectively. The dramatic reduction of 
cardiotoxicity as well as the passive tumor targeted effect were the 
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main benefits of this liposomal formulation (16). Abraxane is approved 
for the treatment of metastatic breast cancer in 2005. Because the 
harmful excipient Cremophor EL was excluded in this formulation, the 
main advantage of Abraxane was the improved toxicity profile (17, 18). 
Drug delivery systems of traditional anti-cancer agents now on market 
are summarized in Table 1.  
Table 1. Anti-cancer agents in delivery systems now on the market (adapted 
from (19)). 
Anti-cancer 
agents 
Delivery 
systems 
Trade names Clinical 
application 
Year of 
approval 
Doxorubicin Liposome Doxil AIDS-related Kaposi’s 
sarcoma 
1995 
US 
   Ovarian cancer 1999 
   Multiple myeloma 2007 
Daunorubicin Liposome DaunoXome AIDS-related Kaposi’s 
sarcoma 
1996 
US 
Cytarabine Liposome Depocyt Lymphomatous 
meningitis 
1999 
US 
Paclitaxel Albumin-
bound 
Abraxane Metastatic breast 
cancer 
2005 
US 
Vincristine Liposome Marqibo Acute lymphoblastic 
leukemia 
2012 
US 
Paclitaxel Micelle Genexol-PM Breast cancer 
Small cell lung cancer 
2007  
Korea 
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Table 2. Polymer drug conjugates presented in clinical trials or on the market 
(adapted from (20, 21)). 
Conjugates Name Company Indication Status 
PEG-irinotecan NKTR-102 Nektar Solid tumor Phase II/III 
PEG-SN38 EZN-2208 Enzon Solid tumor Phase II 
PEG-docetaxel NKTR-105 Nektar Solid tumor Phase I 
PEG-
camptothecin 
Pegamotec
an 
 Gastric 
cancer 
Phase II 
PEG-paclitaxel  Enzon Solid tumor Phase I 
(terminated) 
PHPMA-platinum AP5280 Access 
Pharmaceuti
cals 
Various 
malignancies 
Phase II 
PHPMA-DACH-
oxaliplatin 
ProLinda Access 
Pharmaceuti
cals 
Ovarian 
cancer 
Phase II 
Fleximer-
camptothecin 
XMT-1001 Mersana Gastric 
cancer, lung 
cancer 
Phase I 
Carboxymethyl 
dextran-T2531 
Delimotecan Daiichi 
Pharmaceut
icals 
Various 
malignancies 
Phase I 
Cyclodextrin-
camptothecin 
CRLX101 Cerulean Advance 
solid tumor 
Phase II 
Polyglutamic 
acid-
camptothecin 
CT-2106 Cell 
Therapeutics 
Colon 
cancer, 
ovarian 
cancer 
Phase I/II 
Polyglutamic 
acid-paclitaxel 
Opaxio, 
CT-2103 
Cell 
Therapeutics 
Lung cancer, 
ovarian 
cancer 
Phase III 
HSA-
methotrexate 
MTX- 
HSA 
Klinge 
Pharma 
Kidney 
cancer 
Phase II 
Carboxymethylde
xtran polyalcohol 
polymer-DX-8591 
DE-310 Ontario 
Institute for 
Cancer 
Research 
Various 
malignancies 
Phase I/II 
HPMA-paclitaxel PNU166945 Pharmacia&
Upjohn 
Solid tumor Phase I 
(terminated) 
HSA, human serum albumin.  
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In addition to nano-carrier based systems, polymer-drug conjugate is 
another effective approach to improve therapeutic properties of anti-
cancer drugs. Polymer-drug conjugates can benefit from the 
enhanced permeability and retention (EPR) effect when injected 
intravenously due to the relatively large particle size. Polymer-drug 
conjugates define that therapeutics are covalently linked to polymer 
carriers and are able to be released in active forms. Hydrophilic 
polymers PEG, N-2-Hydroxypropyl methacrylamide (PHPMA), and 
polyglutamic acid (PGA) are frequently involved in this strategy. Table 
2 summarized the polymer drug conjugates in clinical trials or already 
on market currently. 
1.4 Other novel treatments 
Different from traditional nonspecific chemotherapy, targeting 
alternations in oncogene-driven cancers and immune-oncology are 
two main trends in novel cancer therapy. These targeting treatments 
have achieved therapeutic effects that improved survival of patients in 
some type of cancers. 
EGFR downregulating treatments. Epidermal growth factor (EGF) and 
its receptor (EGFR) are crucial for the progression of solid tumors. 
EGFR is highly expressed in NSCLC (22). Various parts of the EGFR 
pathway is related with the growth of tumor cells in lung cancer. Thus, 
EGFR pathway is an attractive target for the treatment of lung cancer. 
Currently, two major approaches downregulating EGFR-signalling are 
anti-EGFR antibodies and EGFR tyrosine kinase inhibitors. Cetuximab 
(Erbitux®) is the representative of anti-EGFR antibodies and gefitinib 
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(Iressa®) is the representative of EGFR tyrosine kinase inhibitors.  
Immunotherapy. Many solid tumors are immunogenic. Tumor related 
antigens resulting from gene mutations are generated during the 
malignancy (23). These antigens could be recognized by the immune 
system. Tumor antigen – specific T cells responses are then initiated 
(23). However, cancer cells can form immune-suppressive networks, 
which disturbs the generation of tumor-reactive T cells and T-cell 
trafficking (24). Therefore, immune-suppressive inhibitory molecules 
(e.g., cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell 
death protein-1 (PD-1), and programmed death-ligand 1 (PD-L1)) are 
the most popular targets for cancer immunotherapy (25). PD-1/L1 
blockers showed very promising clinical results with better toxicity 
profile compared with conventional chemotherapy, particularly in 
melanoma, NSCLC and kidney cancer. PD-1 inhibitor nivolumab 
(Opdivo®) achieved encouraging long-term overall survival results in 
patients with NSCLC, which demonstrated its supior clinical efficacy 
(26).  
2. Inhaled chemotherapy 
2.1 Advantages of inhaled chemotherapy 
Inhaled chemotherapy is considered very promising to treat lung 
cancer because of the targeted delivery with less systemic side effects. 
The concept of “magic bullet” therapy proposed by Paul Ehrlich 100 
years ago illustrates the ideal approach to treat cancer, that is, the 
therapeutics toxic to tumors are targeted to cancer cells without 
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causing damage to healthy tissues and cells (27).  Aerosol 
chemotherapy could achieve the targeted delivery with fewer side 
effects which is the main function of this “magic bullet”. Local exposure 
of the lungs to chemotherapeutics could be achieved. Moreover, 
because the anticancer agents are delivered locally, the dosages 
should be much lower than following intravenous injection, which 
results in higher drug concentrations at the site of lung malignancy and 
lower drug entry into the systemic circulation. Consequently, systemic 
side effects could be minimized due to the relatively low plasma level 
of anti-neoplastic drugs. Finally, inhaled chemotherapy could also 
increase the convenience and compliance of the patients compared 
with intravenous injection. 
Many proof of concept studies have been done in the field of inhaled 
chemotherapy. This approach was first investigated by Tatsumura et 
al. in 1983 using 5-fluorouracil administered to patients by a 
supersonic nebulizer (28). They found remarkable anti-tumor 
responses in patients and only trace amounts of 5-fluorouracil were 
found in the serum samples of tested patients. In 1993, Tatsumura et 
al. also evaluated 5-fluorouracil in dogs by inhalation and obtained 
high concentrations of drug in trachea, hilar bronchi, and regional 
lymph nodes (29). In the following 2 decades, various 
chemotherapeutics were studied for efficacy and safety in either 
animals or humans (30-32). A study was conducted in dogs with 
spontaneously occurred primary and metastatic tumors in the lungs to 
investigate the safety and anti-tumor efficacy of inhaled paclitaxel or 
doxorubicin (33). Anti-tumor efficacy was demonstrated without any 
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acute systemic side effects, i.e., myelosuppression, nausea, and 
vomiting associated in any dogs. They also revealed that a 
combination of both the intravenous and inhaled routes of 
administrating chemotherapeutics enhanced anti-tumor efficacy 
without increasing overall toxicity. These studies based on dogs 
showed that inhaled chemotherapy as a novel therapeutic approach 
could have potential efficacy and safety in humans with lung cancer or 
lung metastasis of other types of cancers. The most recent clinical 
phase II trial in inhaled chemotherapy was conducted with aerosolized 
doxorubicin combined with intravenously delivered platinum (34). It 
showed acceptable toxicity, however, the response rate did not meet 
the objective. Therefore, this treatment was not pursued further.   
Nevertheless, the development and application of inhaled formulations 
for lung cancer face several challenges. The lung itself has a 
sophisticated structure and a very efficient defense system which 
easily clears the substances entering the lung. Moreover, safety 
issues remain major concerns for inhaled chemotherapy. These 
challenges will be discussed in the following sections 2.2 and 2.3. 
2.2 Physiological factors affecting local antitumor efficacy in the 
lungs 
Although inhaled chemotherapy sounds reasonable and attractive 
theoretically, it is not easy to achieve the ideal efficacy. Obstacles 
present in the complexity of lung physiology, including lung barriers, 
epithelial absorption and enzyme systems.  
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2.2.1 Lung barriers 
Airway geometry and particle deposition  
The lung is the site for frequent gas exchange with the environment 
and is consequently exposed to numerous pathogens daily. It has a 
complex structure and includes anatomical barriers to avoid the 
invasion of particles into the lung, thus decreasing the accessibility of 
drugs to the lung. The human lung has been described as a tree of 
which the trachea, bronchi and bronchioles are the branches and the 
alveoli are the leaves (35). The branched nature of the airways leads 
to the impaction of particles in the respiratory tract. Moreover, the 
humid environment in the airways facilitates the growing of 
hygroscopic particle size and then their deposition in the different 
areas of the lung (36).  
Large particles (aerodynamic diameter, daer > 5 μm) deposit in the 
upper respiratory tract by inertial impaction. Particles with 1 to 5 μm 
daer settles down in the central and distal tracts by gravitational settling. 
Most particles with 0.1 and 1 μm daer are exhaled (37). Ultrafine 
particles (<100 nm) quickly deposit in the alveolar region by random 
Brownian movement. Particles below 10 nm deposit in the tracheo-
bronchial region because of high diffusion coefficients (38). Fig. 3 
illustrates the total and regional deposition predicted by the 
International Commission on Radiological Protection (ICRP) 
deposition model. The ICRP model was used to estimate the dose to 
human organs after the inhalation of radioactive particles. Three levels 
of exercise were included in this model: sitting, light exercise, and 
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heavy exercise (39).  
 
Fig. 3 Predicted particle deposition in total and in different respiratory regions 
for light exercise (nose breathing) based on ICRP deposition model. Average 
data from males and females (39). 
Mucus barrier 
After deposition in the lung, the particles are trapped in another barrier, 
the mucus. The mucus is a viscoelastic gel composed of 95% water, 
2% mucin, 1% albumin, immunoglobulins and enzymes and < 1% 
lipids. Mucin is a glycoprotein with a fibrous structure which provides 
the gel property of the mucus (40).  
Mucociliary escalator and phagocytosis are considered as two major 
mechanisms of the clearance of particles in the lung. The mucus is 
secreted continuously and it has a transport velocity around 10-100 
μm/s which facilitates the mucociliary clearance (40), resulting in the 
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movement of mucus and particles trapped in it to the oropharynx, 
where they are swallowed or expelled out (Fig. 4). Phagocytosis by 
alveolar macrophages is the major pathway to eliminate microparticles 
and large proteins depositing in the alveoli. However, particles smaller 
than 200 nm are not efficiently cleared by phagocytosis, which may 
then cause nanotoxicity (41). These highly defensive mechanisms 
protect the lung from hazardous pathogens and particles, however, 
they become major obstacles for drugs to be delivered to the targeted 
site in the lung. Mucociliary clearance has been considered to be the 
cause of the short retention times of nanoparticles that administrated 
to the airways.   
 
Fig. 4 Illustration of mucociliary clearance. The mucus absorbs large 
particles and, with the assistance of the cilia and cough, the harmful particles 
are exhaled (adapted from (42) ). 
Particles that escape from mucociliary clearance of the mucus then 
start to diffuse throughout. The speed of diffusion in mucus is related 
to the particle size. A study has tested the diffusion constants of 
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particles with various sizes in fresh samples of human cervico-vaginal 
mucus. The results were presented as the ratio of diffusion constant 
in mucus, Dmucus, divided by the diffusion constant in PBS, Dpbs (Fig. 
5). It was observed that soluble globular protein with particle size less 
than 100 nm could diffuse freely through the mucus (Dmucus/Dpbs = 1). 
PEGylated nanoparticles with size of 500 nm can still diffuse through 
mucus but at a slow rate. As particle diameter increases, the speed of 
diffusion is slowed down (43). Because the general properties of 
mucus secreted from various epithelia are similar, i.e., they are 
viscoelastic gel containing mucin, water, salts, lipid and protein, this 
cervico-vaginal model could be used to predict the diffusion of particles 
in the lungs. Therefore, choosing a specific size for particles to escape 
or to stay in the mucus could fulfill different purposes when designing 
drug delivery systems (44). 
 
Fig. 5 Diffusion constants in mucus compared with PBS represented as a 
function of hydrodynamic diameter of the diffusing particles (40). 
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2.2.2 Epithelial absorption 
Absorption occurs when the drug solubilized in the mucus passes 
through the epithelium. It has been previously investigated that the 
lung is highly permeable to a number of drugs. Water solubility, 
lipophilicity, and molecular weight play important roles. Small lipophilic 
molecules (log P > 0) have a very short half-life for absorption (around 
1 minute). Small hydrophilic molecules (log P < 0) have half-lives 
around 1 hour (Fig. 6) (45). Hydrophilic macromolecules are absorbed 
much more slowly into the blood stream than hydrophilic small 
molecule drugs (Fig. 7). By using a large molecule carrier to form 
stable delivery systems, the local residence time as well as the local 
concentration of anticancer agents could be improved. For instance, 
Polyethylene glycol (PEG) with large molecular weight (mw >5 kDa) 
has been shown to be retained in the lung for up to 7 days (46). This 
prolonged retention time in the lung can be utilized to achieve 
sustained drug release in the lung by conjugating small molecule 
drugs to macromolecules.  
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Fig. 6 The half-life of drug absorption is depended on the lipophilicity. P 
represents the octanol/water partition coefficient. Half-life represents the 
time taken for absorption of 50% of the initial dose through the lung following 
intratracheal administration in rats (45).   
 
Fig. 7 The half-life of drug absorption through the lung is related to the 
molecular weight. Molecules characterized as lipid-insoluble or as lipid-
soluble are shown as squares and triangles, respectively. Molecules with 
active uptake are shown as inverted triangles (45). 
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At the tumor site, changes in some physical factors could affect drug 
diffusion and absorption. For example, tumors lack functional 
lymphatics. The lymphatic drainage is absent, which results in 
increased high interstitial fluid pressure in tumors (47). Consequently, 
the diffusion and distribution of drugs in tumor can be affected, 
resulting in reduced convection and limited distribution of drugs.  
2.2.3 Enzymatic system of the lung 
Although the lung is not a major site for metabolism, all the 
metabolizing enzymes existing in the liver are found in the lung but in 
lower amounts. The groups of metabolizing enzymes identified include 
phase I CYP-450s, phase II conjugating enzymes, ubiquitous esterase 
and other enzymes. The regional distribution of these enzymes is 
heterogeneous and there are differences between cell types, even 
within the same airway section. The nonspecific esterase is widely 
distributed in the lung tissue. It is present at a high level in alveolar 
macrophages and to a lesser extent in alveolar type I and II cells. 
Esterase can act on esters, amides and thioesters, which allows the 
delivery of prodrugs containing such linkers to be one strategy for 
inhaled chemotherapy (48).    
2.3 Safety issue of chemotherapeutics delivered to the lungs 
Although various anti-cancer drugs and delivery systems have been 
designed and tested for pulmonary delivery, the concerns of efficacy 
versus toxicity to the lung tissue remain debatable. Firstly, pulmonary 
toxicity reactions could happen when using chemotherapeutic agents 
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such as paclitaxel, and docetaxel. This may occur during or after 
treatment (24). Furthermore, local delivery of high doses of 
chemotherapeutic agents can increase the risk of drug-induced 
disease in the lung in patients who usually already have impaired lung 
functions as a result of tobacco-related illness (25). Moreover, the 
occupational exposure to health professionals during treatment is also 
an issue. The nebulized drug must, for instance, be administered in a 
well-ventilated room (26).  
Lung injury can be induced after administration of chemotherapeutics 
either by i.v. Infusion or inhalation. Patients are found to have lung 
interstitial fibrosis and pneumonitis while receiving systemic 
chemotherapy. Inhalation of chemotherapeutics forces the lung to be 
exposed directly to the cytotoxic drug, which would generate even 
more safety problems. Drug induced damage could happen both in the 
airways and in the lung parenchyma (42). 
Airways damages. Bronchoconstriction, which is a lung’s defense 
mechanism, is the major symptom observed after the inhalation. This 
can be found immediately after administration. Nonproductive cough 
is consequently found and the can last several minutes to months. 
Bonchitis obliterance is another dangerous symptom induced by 
inhalation of drugs (49). Neutrophil infiltration and granuloma tissue 
generation can be found in the airway. Peripheral neuropathy can also 
be observed as the neurological adverse effect (50). It is 
recommended that pre-administration of inhaled corticosteroids could 
help to moderate the airways symptoms (47).  
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Lung parenchyma damages. Noncardiologic pulmonary edema can 
occur as an acute toxicity effect induced by interaction of cytotoxic with 
the lung parenchyma. Acute respiratory distress can also be observed 
as a symptom (51). Diffuse pneumonitis and interstitial fibrosis can be 
found either as an acute or chronic injury. The pathological alterations 
behind these adverse effects are: pneumocyte cells type I which 
covering the alveoli surface are destroyed; pneumocyte cells type II, 
which is the ancestors of type I, being reproduced in a larger number; 
However, abnormal type I cells are finally produced due to toxicity 
burden and the limited time. Hypersensitivity pneumonitis is another 
drug induced disease which can be observed either in acute or chronic 
forms. Fever and nonmucus productive cough are usually found as 
symptoms. In this case, eosinophil infiltration in the alveoli and 
interstitial lung tissue is usually observed (42).  
Study of inhaled doxorubicin and paclitaxel based on dogs showed 
acute pulmonary toxicity, including nonproductive cough, which was 
observed in 50% of the tested dogs (33). This side effect was 
presumably associated with the direct interaction of doxorubicin with 
the airways, which resulted in the damages of airways. Mild 
pneumonitis, multifocal interstitial fibrosis and alveolar histiocytosis 
which represents the lung parenchyma damages were also found.  
In a phase I clinical trial of inhaled doxorubicin on patients with 
metastatic tumors to the lungs, the most frequent pulmonary side 
effect was cough (31). Dyspnea, chest pain, wheezing, hoarseness, 
hemoptysis, and bronchospasm were also observed. Sever 
pulmonary adverse effects i.e., hypoxia and respiratory distress were 
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observed in a limited number of patients. One patient received the high 
dose of doxorubicin (9.4 mg/kg) died during the study. The patient was 
a 50-year-old male with bronchoalveolar carcinoma involving both 
lungs. He experienced severe shortness of breath and decreased 
oxygen saturation following the first dose of inhaled doxorubicin. 
Autopsy showed that mucinous bronchoalveolar carcinoma was 
extensively presented in the lungs and acute obstructive pneumonia 
was observed. The author attributed the death to the acute obstructive 
pneumonia secondary to extensive tumor load and tumor evading into 
the larger airways.  
2.4 Nanocarrier related issue 
Nanocarrier systems are widely investigated to deliver anti-cancer 
drugs by the pulmonary route but there is also safety issues related to 
nanoparticles. After administration into the lungs, some nanoparticles 
may be transported to sites out of the lungs and reach non-targeted 
tissues. These properties can lead to potential toxicity as well. In some 
cases, nanoparticles are translocated into interstitial sites, where they 
obtain access to the blood circulation via lymphatics, leading to 
distribution to the whole body (52-54). Furthermore, the ultrafine 
nanoparticles are not easy to be phagocytized by macrophages as 
mentioned before, therefore, they are difficult to be eliminated from the 
alveoli (55). This kind of nanoparticles could stay either in epithelial 
cells or transport to the interstitium, consequently, long-term 
accumulation and toxicity issues could be aroused by them(56). 
Moreover, the toxicity data in vitro is hard to predict the performance 
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of nanoparticles in vivo in lungs. Studies by Sayes et al. that 
demonstrated very little correlation between in vitro and in vivo 
toxicities of nanoscaled zinc oxide and fullerenes (57, 58). 
2.5 Pulmonary delivery of paclitaxel 
Paclitaxel is one of the most effective broad-spectrum 
chemotherapeutic agents. It was originally obtained from the needle 
and bark of pacific yew tree. The antitumor mechanism of paclitaxel 
results from the stabilization of microtubules. This inhibits cell growth 
by preventing cytoskeletal microtubule depolymerization, leading to 
the cessation of the cell cycle (59). Paclitaxel has been widely used in 
clinics for the treatment of a wide spectrum of cancer, such as small 
and non-small cell lung cancer, ovarian cancer, breast cancer, bladder 
cancer, and colon cancer (60). However, the clinical application of 
paclitaxel is limited due to its low aqueous solubility. There is no 
functional group on the structure of paclitaxel to form salt to increase 
its dissolution rate in aqueous solutions (60, 61). The current 
commercial paclitaxel formulation used in the clinic is Taxol, which is 
formulated with 1:1 mixture of Cremophor EL and ethanol and causes 
serious side effects, including hypersensitivity reaction, cardiotoxicity 
and neurotoxicity (62). 
Taxol is administered by the intravenous route, which is not ideal for 
attaining high local drug concentrations in the lungs. In addition, the 
formulation contains an excipient which triggers serious side effects. 
Furthermore, it is clear that administration of free antineoplastic agents 
by aerosol delivery can improve drug accumulation in the lung tumor, 
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but cannot change the toxicity. Therefore, effective and safe 
pulmonary delivery systems of paclitaxel are in need for the clinic. 
In recent years, several delivery systems of paclitaxel have been 
developed and demonstrated potential for pulmonary delivery. In 
these works, paclitaxel was incorporated into different biodegradable 
carriers to form micelles, liposomes, solid lipid nanoparticles or 
microspheres. In particular, polymeric nanoparticles fabricated from 
polymers like poly (ethylene glycol)-b-polycaprolactone (PEG-PCL) 
copolymers, PEG-distearoyl phosphatidylethanolamine (PEG-DSPE), 
alginate, and polyphosphoester polymer p(2,4-diacetylphloroglucinol -
EOP) (P(DAPG-EOP)) have been widely studied (63, 64). 
Paclitaxel liposomes for aerosol treatment was first developed in 2001 
by Koshkina et al. (63). The pharmacokinetics of paclitaxel liposomes 
after inhalation and intravenous administration was compared in 
murine models at the same doses. In the inhalation group, higher local 
concentrations and slow clearance of the drug in the lungs were 
detected. These drug carriers enhance the solubility of paclitaxel by 
encapsulating it and providing a hydrophilic surface. The polymeric 
carriers protect paclitaxel from degradation before reaching the 
targeted site. Local delivery of these paclitaxel systems to the lungs 
could increase the drug concentrations in the tissue, thus improving 
the therapeutic index and reducing the exposure to irrelevant organs 
and tissues. Furthermore, if sustained release is attained, the dosage 
will be decreased drastically and frequent administration will be 
avoided. 
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Although many pulmonary delivery systems have been developed for 
paclitaxel, very few achieved sustained drug release in the lung for a 
long period. In Gill’s research (65), paclitaxel was encapsulated in 
poly(ethylene oxide)-block-distearoyl phosphatidylethanolamine 
(PEG5000–DSPE) micelles. Paclitaxel PEG-DSPE micelles were 
delivered to the lungs of Sprague–Dawley rats directly by intratracheal 
instillation and the tissue distribution and plasma pharmacokinetics of 
the drug were monitored. Initially, a similar drug concentration was 
measured in the lung following paclitaxel delivery using PEG-DSPE 
micelles and Taxol, but after 12h, a much higher paclitaxel 
concentration was found in the lungs with the micelles, which indicated 
a sustained release of paclitaxel. 
3. PEGylation: an useful strategy for inhaled 
chemotherapy  
Attaining a sustained release of drug in the lung would be of great 
benefit. A sustained-release formulation of a chemotherapeutic agent 
could maintain drug concentrations at an effective levels in the lungs 
for a long period of time and avoid peaks in local drug concentration, 
consequently improving the cancer treatments and reducing toxicity to 
lung tissues (66). However, attaining sustained-drug release in the 
lung is challenging. The lung has highly efficient defense mechanisms 
to clear solutes and particulates as described earlier in this chapter 
(67). Different strategies to obtain sustained drug release in the lungs 
have been tested in animal models, including tumor-bearing animals. 
These include PEGylation, dendrimers, biodegradable polymeric 
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microspheres, liposomes, lipid particles, and micelles (68-72). In this 
thesis, we focus on PEGylation of a small molecule anti-cancer drugs 
for pulmonary delivery. Therefore, the concept of PEGylation, its use 
in chemotherapy and pulmonary delivery will be discussed in details 
in the following text.   
3.1 Concept of PEGylation 
Polyethylene glycol (PEG) is a macromolecule which can be 
significantly hydrated in water because of the hydrogen bonds with 
water. PEGylation defines linking one or more PEG to a protein, 
peptide or small molecular drug (73). Depending on its size, PEG can 
be transported and absorbed across the epithelia membranes in the 
lung. Using PEG to formulate small molecule drugs could theoretically 
prolong the retention of drugs in the lung and thus possibly achieve 
sustained release of drugs. PEG is nontoxic and FDA has approved 
its usage in formulations. PEGylation of small molecules can be 
classified according to the general configuration of the system (linear, 
branched, dendrimeric, etc.) or the type of linkage between 
components (ester, amide, biodegradable, nonbiodegradable, etc.) 
(74). 
PEG-drug conjugates have several advantages: 1) The improvement 
of the solubility of hydrophobic drugs, 2) prolongation of residence 
time in the body, 3) reduction of degradation by metabolic enzymes, 
and 4) minimization of protein immunogenicity.  
PEG-drug conjugates can be designed as controlled release systems 
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which are able to release the drugs from conjugates to meet specific 
needs (75). This function can be fulfilled by designing different types 
of linkers. For instance, using particular linkers or bonds sensitive to 
pH could result in the specific release of drug inside the cells. N-
cisaconityl acid spacer and hydrazone linkages could be hydrolyzed 
at the acidic pH of endosomes. H-Gly-Phe-Leu-Gly-OH or H-Gly-Leu-
Phe-Gly-OH spacers could result in breakdown in lysosome by acid 
proteases or aminopeptidases (76). 
The typical problem in small drugs PEGylation is the low drug loading 
percentage due to PEG only possessing one or two functional terminal 
groups. To overcome this limitation, dendrimeric structures or 
branched PEG have been developed. However, these structures may 
cause a decrease in solubility after drug loading. Furthermore, 
synthesis of dendrimer-like or branched PEG remains difficult in terms 
of cost and industrial production (77). 
3.2 PEGylation of chemotherapeutic agents 
Solid tumors have the unique anatomy and pathophysiology which are 
different from normal tissues. Tumor tissues present selective 
extravasation of macromolecules due to the hypervasculature and 
increased permeability of tumor blood vessels. This feature of solid 
tumors is call enhanced permeability and retention (EPR) effect (78). 
For antineoplastic drug, PEGylation could provide a passive targeting 
to solid tumors through the EPR effect when injected intravenously. 
For pulmonary delivery, PEGylation could simply improve the drug’s 
pharmacokinetic profile by slowing down the drug clearance from the 
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lungs. Usually PEG-drug conjugates are considered as 
macromolecular prodrugs, because the loaded drugs are not active 
unless released from the conjugate.  
Various anti-cancer drugs on the market have been PEGylated. These 
drugs include paclitaxel, docetaxel, doxorubicin, gemcitabine, and 
camptothecin. There are several PEGylated chemotherapeutics under 
clinical trials from the two leading companies focusing on polymer-
drug conjugates, i.e., Nektar Therapeutics and Enzon Pharmaceutical. 
PEG-irinotecan (NKTR-102) and PEG-docetaxel (NKTR-105) from 
Nektar, and PEG-SN38 (SN 38, 7-ethyl-10-hydroxy-camptothecin) 
(EZN-1108) from Enzon are now in clinical trials for solid tumors (20, 
73, 79). The recent developments of PEGylated paclitaxel and 
docetaxel, two important anti-neoplastic drugs in the taxane family, will 
be discussed in the following text.  
Paclitaxel 
The clinical application of paclitaxel is limited by the poor aqueous 
solubility and the serious side effects. PEGylated paclitaxel could 
increase its aqueous solubility and at the same time minimize its side 
effects. Linkage to a macromolecule could enable paclitaxel reaching 
the tumor tissue via the EPR effect following intravenous injection. 
Furthermore, sustained release could be obtained due to the slow 
clearance of large PEG molecules from the lung. 
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Fig. 8 PEG-paclitaxel synthesized by Greenwald et al. Paclitaxel was 
conjugated to a bi-functional PEG by ester bonds (adapted from (80) ). 
In 1996, Greenwald et al. synthesized several PEG-paclitaxel 
conjugates with different molecular weights of 6 kDa, 20 kDa and 40 
kDa (Fig. 8) (80). Paclitaxel was covalently linked to PEG by 
esterification. Then this PEG-paclitaxel has been involved in clinical 
trial phase I for solid tumor and lymphomas with pharmaceutical 
company Enzon in 2001. However, the phase I clinical trials was 
terminated in 2003 based on a strategic analysis of the program's 
potential returns against the associated costs, competitive risks, and 
development time (77, 81). Pendri et al. (82) developed PEG-
conjugated paclitaxel-2¢-glycinate. Glycine was used as a spacer. The 
prodrug is structured with an amide bond between glycine and PEG 
and an ester bond between glycine and paclitaxel. This water-soluble 
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form of paclitaxel showed lower toxicity and enhanced antitumor 
activity compared with the native drug in a P388/0 murine leukemia 
model following intraperitoneal injection. The author attributed these 
advantages to the tripartite nature of the conjugate. The prodrug would 
first break down at the amide bond and release the glycine ester-
paclitaxel moiety extracellularly, due to the high levels of 
aminopeptidases and lysosomal acid proteases. Then, the rapid 
cleavage of the ester bond between paclitaxel and glycine would 
release the free drug.  
 
Fig. 9 PLA-PEG-PLA/paclitaxel conjugate (83). 
Another example is a poly(lactic acid)-b-poly(ethylene glycol)-b-poly 
(lactic acid) (PLA-PEG-PLA)/paclitaxel conjugate synthesized by Xie 
et al. (Fig. 9) (83). This conjugate can self-assemble into micelles in 
an aqueous phase. It was shown that the conjugate had high 
cytotoxicity against Hela cancer cells, which indicated that paclitaxel 
had been released in an active form and the anti-tumor efficacy had 
been maintained. 
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Docetaxel 
Docetaxel is an anti-mitotic chemotherapeutics for treatments of non-
small cell lung cancer, advanced or metastatic breast cancer, gastric 
cancer and hormone-refractory prostate cancer. Docetaxel is sold on 
the market as Taxotere or Docecad.  
PEGylated docetaxel (NKTR-105) was produced by Nektar with multi-
arm PEG (Fig. 10). In the preclinical study in rats and dogs, NKTR-
105 improved the PK profile of docetaxel by reducing its peak 
concentrations and prolonging its half-life. NKTR-105 showed superior 
activity over docetaxel in murine models of human lung, colon, and 
prostate carcinomas. A significant and prolonged delay in tumor 
growth was observed in the group receiving NKTR-105 (84, 85). This 
conjugate has entered phase I clinical studies for investigation of its 
safety property.  
 
Fig. 10 The drug release mechanism of PEGylated docetaxel (NKTR-105) 
(85). 
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3.3 PEGylation for pulmonary delivery 
PEGylation has been used in pulmonary delivery to attain sustained 
drug release in the lungs. PEGylation of proteins are commonly used 
to protect the therapeutics from degradation and thereby enhance the 
local efficacy. For instance, monomethoxy-PEG-750-insulin showed 
long t1/2 for 12h, which is twice as long as that detected for regular 
insulin (86). In addition, PEGylated antibody fragments such as anti-
interleukin-17A (IL-17A) F(ab′)2 and anti-IL-13 Fab′ greatly prolonged 
the presence of these fragments in the lungs. The PEGylated antibody 
fragments were retained in the lungs for up to 4 h post-delivery and 
persisted in the lungs for more than 2 days. However, the clearance of 
the unconjugated proteins commenced immediately after 
administration and was mostly completed within one day (87). 
Christopher J. Morris et al. (88) tested the hypothesis that PEGylation 
of an inhaled antimicrobial peptide could reduce its pulmonary toxicity 
while offering stable and effective antimicrobial activity. They 
administered the PEGylated peptide via the airways in an isolated 
perfused rat lung (IPRL) model and concluded that PEGylation may 
enhance the lung biocompatibility of antimicrobial peptides. 
Besides, PEGylation of excipients is widely used to increase drug 
retention and enhance efficacy. For instance, different formulations of 
PEGylated liposomes loaded with antisense oligonucleotides，and 
small interfering RNA were developed and delivered intratracheally to 
mice (89). Recently, the behavior of PEGylated dendrimers was 
studied in the lungs (90). The authors explored the potential of 
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PEGylated polylysine dendrimers as drug carriers for pulmonary 
application and the relationship between dendrimer size, absorption of 
the particles and retention in the lungs. Approximately 20−30% of the 
relatively small PEGylated dendrimers (<22 kDa) were absorbed in to 
systemic circulation within 48 h compared with only 2% absorption of 
a large dendrimer (78 kDa) within 7 days. As the molecular weights of 
the dendrimers increase, the absorption slows down. Prolonged 
retention in the lung can be achieved. 
However, reports on pulmonary delivery of PEGylated small molecule 
drugs are rare in the literature. PEG-prednisolone conjugates were 
developed for asthma and chronic obstructive pulmonary disorder 
therapies and assessed in vitro and ex vivo in isolated and perfused 
rat lung (91). PEGylated prednisolone showed reduced maximum 
blood concentration (Cmax) and prolonged absorption as compared to 
the free drug. The Cmax of PEG-prednisolone was reduced by a factor 
3 and tmax increased by 45%, compared to prednisolone. The t1/2 
absorption from the lung was 1 min with prednisolone and 8 min with 
PEG-prednisolone (Fig. 11).  
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Fig. 11 Normalized absorption profiles of prednisolone in the isolated 
perfused rat lungs obtained with (□) prednisolone alone, (○) mPEG2000-
Pred and (Δ) PEG2000-Pred2. Prednisolone concentration (nmol L− 1) 
measured in perfusate was divided by the actual delivered dose (nmol) to 
give a relative prednisolone fraction (L− 1). Data are presented as mean ± SD, 
n = 3. (91) 
Up to date, there is no report about PEGylated anti-cancer drugs for 
inhaled chemotherapy though they have been widely investigated by 
the intravenous route. Therefore, exploration of the pulmonary delivery 
of PEGylated small molecular chemotherapeutics is needed. 
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4. Aim of the thesis 
The objective of this project is to explore the application of polymer 
drug conjugates in inhaled chemotherapy. PEGylation of anti-
neoplastic drugs was chosen as a strategy. Polyethylene glycol (PEG)-
paclitaxel conjugates (PEG-PTX) for pulmonary delivery were 
designed in order to achieve improved anti-cancer efficacy with 
reduced local toxicity. PEG-PTX were expected to present sustained 
release of PTX in the treatment of lung cancer, as compared to the 
quickly-cleared native drug.  
Paclitaxel (854 Da) was designed to link to PEG of large molecular 
weights (6 kDa and 20 kDa) by an ester bond. As the hydrolysis of the 
ester bond proceeds, PTX will be released progressively in the lung 
fluid. Our hypothesis was that the macromolecule will permit paclitaxel 
retention in the airspaces for a prolonged time period, as compared to 
free paclitaxel. The present strategy would be beneficial for cancer 
therapy, because improved tumor exposure to anti-neoplastic drugs 
would be achieved by sustained drug release from conjugates.  
Paclitaxel was chosen as a model drug for our project. It is used in 
first-line treatments of lung cancer. It is poorly-water soluble and 
conjugation with PEG, a highly hydrophilic polymer, will increase its 
solubility. PEG (molecular weights 6k Da and 20k Da) has been 
chosen because it is proved that large PEG (molecular weight > 5 kDa) 
has a long retention time (7 days) in the lung tissue, which could 
enable a sustained drug release from PEG-paclitaxel conjugate in the 
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lung (46). Meanwhile, it is nontoxic and non-biodegradable but it can 
be eliminated by renal and hepatic pathways. It has already been 
approved for human use in dosage forms for intravenous, oral and 
inhalation applications. 
2’-OH on paclitaxel was chosen to be conjugated to PEG by an ester 
bond. 7-OH and 1-OH were not chosen because of the steric 
hindrance. Although 2’-OH is necessary for the activity of paclitaxel, 
as the hydrolysis of the ester bond proceeds, paclitaxel will be 
released in active form (Fig. 12). Two structures of the conjugates 
were designed: 1) paclitaxel was conjugated to PEG by “click” 
chemistry; 2) a succinic spacer was used to link paclitaxel to PEG (Fig. 
13).  
 
Fig. 12 Structure-active relationships (SARs) of paclitaxel (77) 
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Fig. 13 Two structures of PEG-PTX conjugates developed in this thesis. 
In this thesis, PEG-PTX were synthesized and characterized physico-
chemically. The in vitro evaluation was conducted to investigate 
stability of PEG-PTX in different medium and cytotoxicity to cancer 
cells. Afterwards, acute toxicity of PEG-PTX was investigated in mice 
to determine the maximum tolerated doses. Local toxicological studies 
were conducted on mice to understand the toxicity of PEG-PTX to the 
lungs. Further, Anti-tumor efficacy of PEG-PTX was studied on a 
murine lung carcinoma model. The efficacy of intratracheally and 
intravenously administrated treatments were compared. Finally, in vivo 
release of paclitaxel and the retention of PEG-PTX conjugates in 
mouse lungs were investigated. 
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“Rien ne se perd, rien ne se crée, tout se transforme.” 
“Nothing is lost, nothing is created, everything is transformed.” 
－ Antoine Lavoisier 
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ABSTRACT  
Pulmonary drug delivery is considered an attractive route of drug 
administration for lung cancer chemotherapy. However, fast clearance 
mechanisms result in short residence time of small molecule drugs in 
the lung. Therefore, achieving a sustained presence of 
chemotherapeutics in the lung is very challenging. In this study, we 
synthesized two different polyethylene glycol-paclitaxel ester 
conjugates with molecular weights of 6 kDa and 20 kDa in order to 
achieve sustained release of paclitaxel in the lung. One structure was 
synthesized with azide linker using “click” chemistry and the other 
structure was synthesized with a succinic spacer. The 
physicochemical and biological properties of the conjugates were 
characterized in vitro. Conjugation to PEG improved the solubility of 
paclitaxel by up to four orders of magnitude. The conjugates showed 
good stability in phosphate buffer saline pH 6.9 (half-life ≥ 72 h) and in 
bronchoalveolar lavage (half-life of 3 to 9 h) at both molecular weights, 
but hydrolyzed quickly in mouse serum (half-life of 1 to 3 h). The 
conjugates showed cytotoxicity to B16-F10 melanoma cells and LL/2 
Lewis lung cancer cells but less than free paclitaxel or Taxol, the 
commercial paclitaxel formulation.These properties imply that the 
conjugates have the potential to retain paclitaxel in the lung for a 
prolonged duration and to sustain its release locally for a better 
efficacy.   
Adapted from : Synthesis and in vitro evaluation of polyethylene glycol-paclitaxel conjugates 
for lung cancer therapy. Pharmaceutical Research. 16 Mar 2016. 
Authors : Tian Luo • Johannes Magnusson • Véronique Préat • Raphael Frédérick • Cameron 
Alexander • Cynthia Bosquillon • Rita Vanbever  
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1. Introduction 
Lung cancer is the most common cancer worldwide and caused 1.6 
million deaths in 2012 (92). Systemic chemotherapy is widely used in 
the treatment of lung cancer, but the clinical efficacy is unsatisfactory 
as a result of the low local drug concentrations in the lung tumors and 
the severe dose-limiting side effects. Pulmonary delivery of 
chemotherapeutic agents is considered an attractive route of 
administration, with the advantages of high drug concentrations locally 
and low side effects systemically. However, small molecules have very 
short half-lives of absorption from the lung to the systemic circulation 
(93). In general, small hydrophilic compounds (log P<0) have a half-
life to absorption of approximately 1 hour, whereas lipophilic small 
molecules (log P>0) are absorbed in approximately 1 minute. This 
rapid systemic absorption results in a short residence time of 
chemotherapeutics in the lung. In addition, inhalation of 
chemotherapeutics alone would lead to transient high drug 
concentrations locally and unacceptable toxicity to the lung tissue (94). 
Therefore, drug carriers could provide promising application for the 
pulmonary administration of anti-cancer agents in lung cancer with 
prolonged drug retention and sustained drug release locally as well as 
with reduced lung toxicity compared to the pulmonary delivery of the 
free drug (95).  
Several nanocarrier-based pulmonary delivery systems have been 
developed and evaluated as potential treatment for lung cancer after 
inhalation, such as polymeric nanoparticles of doxorubicin and 
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liposomes of paclitaxel (PTX) (32, 96). However, the control of the 
release kinetics is difficult to achieve with these delivery systems. 
Moreover, the absorption of the therapeutics across pulmonary 
epithelia to lung tumors and the drug distribution in tumors are 
expected to be decreased due to the relatively large size and surface 
charges of these nanocarrier systems (97, 98). 
Conjugation of drugs to macromolecules by means of esterification 
provides a possible mechanism by which drugs could be retained in 
the lung due to the long residence times of macromolecules in the 
airspaces (93). Polyethylene glycol (PEG) is widely used in drug 
delivery and it has been shown that PEG with large molecular weight 
(MW > 5 kDa) can be retained in the lung for up to 7 days (99). This 
could enable a sustained release of a drug conjugated to PEG by 
hydrolysis of the ester bond between the polymer and the drug (87, 
91, 99). Moreover, the polymer-drug conjugates will be taken into the 
cells by endocytosis (100, 101), which could possibly avoid multi-drug 
resistance mediated by efflux pumps (102, 103). As compared to 
carrier particles and micelles, drug loading is relatively high for 
conjugates (10-30%) (104). In addition, as the conjugates will be 
delivered in solution, the size of this carrier will be very small (< 10 
nm), which will not generate the problem of tumor access. 
PTX is a first-line drug for lung cancer treatment but it is poorly water 
soluble. Taxol, the commercial formulation of PTX, contains 
Cremophor EL to increase the drug solubility. However, Cremophor EL 
is well-known for its severe toxicity and its impact on PTX 
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pharmacokinetics. Cremophor EL alters PTX pharmacokinetic 
behaviour to a non-linear profile (105-107). Conjugation to highly 
hydrated PEG could largely increase PTX solubility without inducing 
unexpected toxicity (108, 109). In fact, PEG is nontoxic and it can be 
eliminated by mucociliary clearance and by renal and hepatic 
pathways (87). It has already been approved for human use in dosage 
forms for intravenous, oral and inhalation applications (110). Several 
studies have reported the synthesis of polymer-PTX conjugates in the 
literature. For instance, poly (L-glutamic acid)-PTX (Opaxio™) has 
already reached phase III clinical trials for ovarian cancer (111) and 
this conjugate showed reduced toxicity when locally delivered to the 
lung of mice (112). There are also various studies on PEG-PTX 
conjugates in the literature (80, 113-116). However, the pulmonary 
application of PEGylated PTX for lung cancer and the evaluation of its 
properties for lung cancer therapy both in vitro and in vivo have not 
been explored.  
Therefore, the aim of this study was to develop water soluble and 
stable PEG-PTX conjugates for pulmonary application in lung cancer. 
Two conjugates with either an azide linker (PEG-N3-PTX) or a succinic 
linker (PEG-suc-PTX) were designed with 6 kDa and 20 kDa MW PEG 
(Fig. 14). Linear PEGs were modified with PTX at both hydroxyl ends 
to increase the drug load in the final products. PTX was linked to the 
PEG molecule via an ester bond at the C-2’ position on PTX side chain. 
Although the hydroxyl on the C-2’ is necessary for PTX activity, the 
chemical and enzymatic hydrolysis of the conjugate in the lung could 
offer a progressive release of active PTX with free C-2’ hydroxyl. 
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Moreover, the C-2’ position on PTX does not present steric hindrance 
as the hydroxyl 1-OH and 7-OH on the taxane ring do and could permit 
a high conversion rate. We used “click” chemistry in one of the 
synthetic routes because of the high efficiency of the azide and alkyne 
reaction. Moreover, the triazole formed between alkyne and PEG-
azide is very stable and cannot hydrolyze before the ester bond. 
Consequently, the free PTX will release from the conjugate in an active 
form. All the conjugates were characterized physically and chemically 
and stability as well as cytotoxicity were evaluated in vitro.  
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Fig. 14 Synthetic routes of PEG-PTX conjugates. A. “Click” chemistry 
route: PTX (compound 1) was modified with pentynoic acid at C-2’ group to 
obtain PTX-alkyne (compound 2). PEG-N3 6 kDa and 20 kDa (compounds 
5a and 5b) were synthesized from PEG with 2 hydroxyl ends by tosylation 
followed by azidation. PTX-alkyne was then conjugated to PEG-N3 6 kDa 
and 20 kDa via “click” chemistry respectively to obtain the final conjugates 
PEG-N3-PTX 6 kDa and 20 kDa (compounds 6a and 6b). B. Succinic 
spacer route: succinic acid was linked to PEG 6 kDa and 20 kDa via 
esterification to obtain PEG-suc 6 kDa and 20 kDa (compounds 7a and 7b). 
PEG-suc-PTX 6 kDa and 20 kDa (compounds 8a and 8b) were then obtained 
by esterification of PEG-suc and PTX at C-2’ position. 
B 
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2. Materials and methods  
2.1 Materials and instruments  
PEG with two hydroxyl terminals and MW of 6 kDa and 20 kDa were 
purchased from Iris Biotech (Marktredwitz, Germany). Paclitaxel was 
purchased from Chemieliva (Chongqing, China). Taxol was obtained 
from Brystol-Myers Squibb.  N,N'-diisopropylcarbodiimide (DIC), 4-
dimethylaminopyridine (DMAP), tysol chloride, trimethylamine (TEA), 
dichloromethane, dimethyl sulfoxide (DMSO), acetonitrile, 
dimethylformamide (DMF), and Cremophor EL (Kolliphor® EL) were all 
purchased from Sigma Aldrich (Gillingham, UK). Hank’s balanced salt 
solution (HBSS) and Dulbecco's phosphate-buffered saline (DPBS) 
were purchased from Life Technologies (Paisley, UK).  The thiazolyl 
blue tetrazolium bromide (MTT) was from Sigma Aldrich (St. Louis, 
MO, USA). Spectra/Por® 7 Tubing (Spectrum Laboratories, Inc, 
Rancho Dominguez, CA, US) was used to carry out all the dialysis 
work. 
Nuclear magnetic resonance (NMR) spectra were recorded on a 
Bruker 400 MHz spectrometer. Chemical shifts are reported in ppm (δ 
units) downfield from internal tetramethylsilane. Electrospray 
ionisation time-of-flight mass spectrometry (TOF-ES-MS) was 
performed by WATERS-2795 (Waters, UK) and analyzed by 
MassLynx software. 
 
 
CHAPTER 2. SYNTHESIS AND IN VITRO EVALUATION OF POLYETHYLENE GLYCOL-
PACLITAXEL CONJUGATES FOR LUNG CANCER THERAPY 
 
  49 
 
2.2 Synthesis of PEG-N3 6 kDa and 20 kDa 
PEG-N3 was obtained by tosylation followed by azidation. PEG 6kDa 
(1 g, 0.167 mmol, 1.0 equiv.) was dissolved in 5 mL toluene and 
evaporated to dryness for 3 cycles to remove water. The dried PEG 
was dissolved in 5 mL dichloromethane under Argon. The solution was 
cooled to 0 ℃, then tosyl chloride (0.191 g, 1 mmol, 6 equiv.) and 
triethylamine (0.139 mL, 1 mmol, 6.0 equiv.) were added. The solution 
was kept at 0 ℃ for 2 hours and then warmed up to room temperature 
and stirred overnight. The reaction solution was poured into cool 
diethyl ether 3 times to precipitate PEG-bis-tosyl ester. The product 
was then filtered and dried under vacuum overnight. The same 
method and reaction scale were applied for PEG 20 kDa. The yield 
was 80% at both PEG MW. Compounds 4a and 4b: 1H NMR (400 
MHz, D2O, δ in ppm) δ 7.79 (d, J = 8.5 Hz, 4H), 7.45 (d, J = 7.9 Hz, 
4H), 4.20 (d, J = 4.4 Hz, 4H), 3.62 (m, PEG). δ 7.79 and 7.45 ppm 
represented the phenyl protons on the tosyl groups. δ 4.2 ppm 
represented the terminal -CH2 on PEG which was linked to the tosyl 
group.   
PEG-bis-tosyl ester 6 kDa (1.0 g, 0.167 mmol, 1.0 equiv.) and NaN3 
(0.106 g, 1.67 mMol, 10.0 equiv.) were dissolved in 5 mL DMF. The 
mixture was stirred at 90 °C under argon atmosphere overnight. The 
product was precipitated in diethylether to remove DMF. Precipitates 
were dissolved in 10 mL water, and transferred to pre-wetted dialysis 
bags MWCO 2000 Da. Dialysis was carried out against deionized 
water overnight under stirring to remove excess sodium azide and 
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DMF. The product was finally freeze dried. The same method and 
reaction scale were applied to PEG-tosyl 20 kDa. The yield was 80% 
at both PEG MW. Compounds 5a and 5b: 1H NMR (CDCl3, δ in ppm) 
δ 3.77 – 3.58 (m, PEG backbone), 3.41 (t, J = 5.0 Hz, 4H, PEG-O-CH2 
-CH2-N3). FT-IR: 2916.74, 2113.73, 1644.69, 1469.55, 1349.95, 
1297.95, 1251.61, 1097.31, 949.52, 840.07. 
2.3 Synthesis of PTX alkyne 
The synthesis of PTX alkyne has previously been described (117). 
PTX (50 mg, 0.059 mmol, 1.0 equiv.) was dissolved in 5.0 mL 
anhydrous dichloromethane under Argon. 4-Pentynoic acid (6.9 mg, 
0.07 mmol, 1.2 equiv.), DIC (11.1 mg, 0.08 mmol, 1.5 equiv.) and 
DMAP (3.5 mg, 0.03 mmol, 0.5 equiv.) were dissolved in 
dichloromethane under nitrogen. The resulting solution was left to stir 
under Argon at room temperature overnight. The product was purified 
using a silica gel column, and hexane/ethyl acetate 1:1 was used as 
eluent. Thin layer chromatography was used to track the product. 
Samples containing PTX were combined and the solvent was 
removed by vacuum. The product was dried under vacuum overnight. 
The yield was 65%. Compound 2: 1H NMR (CDCl3, δ in ppm) δ 8.19 
(d, J = 7.4 Hz, 2H, 2-OBz), 7.79 (d, J = 7.5 Hz, 2H, 3’-NBz), 7.68 (t, J 
= 7.4 Hz, 1H, 2-OBz), 7.58 – 7.51 (m, 3H, 2-OBz, 3’-NBz), 7.47 – 7.35 
(m, 7H, 2-OBz, 3’-ph, 3’-NBz), 6.32 (s, 1H, C10-H), 6.28 (t, J = 8.9 Hz, 
1H, C13-H), 6.00 (dd, J = 9.2, 3.0 Hz, 1H, C3’-H), 5.71 (d, J = 7.1 Hz, 
1H, C2-H), 5.55 (d, J = 3.1 Hz, 1H, C2’-H), 5.00 (d, J = 7.7 Hz, 1H, C5-
H), 4.51 – 4.43 (m, 1H, C7-H), 4.34 (t, J = 7.1 Hz, 1H, C20-Ha), 4.26 – 
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4.20 (m, 1H, C20-Hb), 3.84 (d, J = 7.1 Hz,1H, C3-H), 2.71 (m, 2H, 
HC≡C-CH2-CH2-COO-PTX), 2.60 (m, 2H, HC≡C-CH2-CH2-COO-PTX), 
2.53 (m, 1H, C6-Ha), 2.51 (m, 1H 7-OH), 2.48(s, 3H, C4-OAc), 2.39 
(m, 1H, C14-Ha), 2.26 (s, 3H, C10-OAc), 2.20 (m, 1H, C14-Hb), 1.97 
(s, 3H, C18-Me), 1.94 (m, 1H, C6-Hb), 1.91 (s, 1H, HC≡C-CH2-CH2-
COO-PTX), 1.68 (s, 3H, C19-Me), 1.26 (s, 3H, C17-Me) 1.15 (s, 3H, 
C16-Me). Signal of δ 5.55 ppm showed that an ester bond was formed 
at the desired C2’ position on the paclitaxel side chain. δ 4.51 – 4.43 
ppm represented the C7 proton, which stayed at the same position as 
the starting material paclitaxel. This verified that no ester bond formed 
at C7 position. Finally, signals of δ 2.71 and 2.60 ppm showed the 
presence of –CH2-CH2- on the pentynoic group and the signal of δ 
1.91 ppm demonstrated the alkyne proton. These information 
confirmed that pentynoic acid was successfully linked on the C2’ 
position of paclitaxel. MS m/z (ES+) calculated from C52H55NO15 : 
934.4 (M+H+) (PTX-alkyne + H+), 856.3 (fragment of PTX). 
2.4 Synthesis of PEG-N3-PTX conjugates 6 kDa and 20 kDa 
PEG-N3 6 kDa (100 mg, 0.016mmol, 1.0 equiv.), PTX alkyne (39 mg, 
0.04 mmol, 2.5 equiv.) and PMDETA (10 µL, 0.05 mmol, 3.0 equiv.) 
were dissolved in 4 mL DMF under nitrogen, and then degassed for 
10 min. Copper bromide (7 mg, 0.1 mmol, 3.0 equiv.) and sodium 
ascorbate (19.5 mg, 0.2 mmol, 6.0 equiv.) were dissolved in 1 mL DMF 
in another vial under nitrogen and degassed for 10 min. The mixture 
of coper bromide and sodium ascorbate were added into the reaction 
flask under nitrogen and degassed for another 10 min. The reaction 
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was stirred at 45 ℃ overnight. The conjugate was first purified by 
precipitation in cold diethylether to remove PTX and catalysts, and 
then by dialysis against water to remove copper bromide. The 20k 
conjugate was produced with the same method. The yield was 70% at 
both PEG MW. Compounds 6a and 6b : 1H NMR (CDCl3, δ in ppm) δ 
8.14 (d, J = 7.4 Hz, 4H, 2-OBz), 7.82 (d, J = 7.5 Hz, 4H, 3’-NBz), 7.62 
(t, J = 7.4 Hz, 4H, 2-OBz), 7.56 – 7.45 (m, 10H, 2-OBz, 3’-NBz, 3’-ph), 
7.42 – 7.33 (m, 12H, triazole, 2-OBz, 3’-ph, 3’-NBz), 6.28 (s, 2H, C10-
H), 6.19 (t, J = 8.9 Hz, 2H, C13-H), 5.94 (dd, J = 8.6, 3.7 Hz, 2H, C3’-
H), 5.67 (d, J = 7.0 Hz, 2H, C2-H), 5.44 (d, J = 3.7 Hz, , 2H, C2’-H), 
4.96 (d, J = 8.5 Hz, 2H, C5-H), 4.53 – 4.39 (m, 6H, PEG-O-CH2-CH2-
triazole, C7-H), 4.31 (d, J = 8.5 Hz, 2H, C20-Ha), 4.19 (d, J = 8.5 Hz, 
2H, C20-Hb), 3.80(m, 6H, C3-H, PEG-O-CH2-CH2-triazole), 3.55-3.75 
(m, PEG), 3.03 (m, 4H, PEG-triazole-CH2-CH2-CO-PTX), 2.85 (m, 4H, 
PEG-triazole -CH2-CH2-CO-PTX), 2.60 – 2.52 (m, 2H, C6-Ha), 2.50 (d, 
J = 3.9 Hz, 2H, 7-OH), 2.42 (s, 6H, C4-OAc), 2.29 (dd, J = 15.4, 9.4 
Hz, 2H, C14-Ha), 2.23 (s, 6H, C10-OAc), 2.06 (dd, J = 15.4, 8.9 Hz, 
2H, C14-Hb), 1.92 (s, 6H, C18-Me), 1.86 (m, 2H, C6-Hb), 1.68 (s, 6H, 
C-19), 1.22 (s, 6H, C17-Me), 1.13 (s, 6H, C16-Me). 
2.5 Synthesis of PEG-suc 6 kDa and 20 kDa 
PEG 6 kDa (1.0 g, 0.167 mmol, 1.0 equiv.) was dissolved in 5 mL 
toluene and evaporated 3 times to remove water. The dried PEG was 
dissolved in dichloromethane under Argon. The solution was cooled to 
0 ℃, succinic anhydride was added (100 mg, 1 mmol, 6.0 equiv.). TEA 
(0.14 mL, 1 mmol, 6.0 equiv.) was dropped with a syringe. The reaction 
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was then kept on ice for 1 hour and was stirred at room temperature 
overnight. The PEG-suc was purified by precipitation in cold 
diethylether 3 times. The precipitates were dried under vacuum at 
room temperature overnight. The same method and reaction scale 
were applied to PEG 20 kDa. The yield was 80% at both PEG MW.  
Compounds 7a and 7b: 1H NMR (CDCl3, δ in ppm) δ 4.22 (t, J = 25.0 
Hz, 4H, PEG-O-CH2-CH2-O-succinic acid), 3.94 – 3.36 (m, PEG 
backbone), 2.71 (d, J = 54.4 Hz, 8H, PEG-COO-CH2-CH2-COOH). 
2.6 Synthesis of PEG-suc-PTX conjugates 6 kDa and 20 kDa 
PEG-suc 6 kDa (100 mg, 0.017 mmol, 1.0 equiv.), PTX (37 mg, 0.04 
mmol, 2.5 equiv.) and DMAP (5 mg, 0.04 mmol, 2.5 equiv.) were 
dissolved in 1.5 mL DCM under nitrogen. The reaction flask was 
placed on ice and DIC (2.0 µL, 0.04 mmol, 2.5 equiv.) was added into 
the flask. The reaction was then stirred overnight at room temperature. 
The conjugate was purified by precipitation in cold diethylether 3 times 
and dried under vacuum. The 20k conjugate was produced with the 
same method but with higher PTX ratio (equiv. 4.0). The yield was 70% 
at both PEG MW.  Compounds 8a and 8b: 1H NMR (CDCl3, δ in ppm) 
δ 8.10 (m, 4H, 2-OBz), 7.85 (m, 4H, 3’-NBz), 7.62 (t, J = 7.4 Hz, 4H, 
2-OBz), 7.56 – 7.45 (m, 10H, 2-OBz, 3’-NBz, 3’-ph), 7.42 – 7.33 (m, 
10H, 2-OBz, 3’-ph, 3’-NBz), 7.33 (t, J = 6.8 Hz, 2H, 3’-NBz), 7.07 (t, J 
= 9.0 Hz, 2H, 3’-NH), 6.29 (s, 2H, C10-H), 6.23 (t, J = 8.7 Hz, C13-H, 
1H), 5.97 (dd, J = 9.1, 3.0 Hz, 2H, C3’-H), 5.68 (d, J = 7.1 Hz, 2H, C2-
H), 5.49 (d, J = 5.5 Hz, 2H, C2’-H), 4.97 (d, J = 7.9 Hz, 2H, C5-H), 4.45 
(m, 2H, C7-H), 4.32 (d, J = 8.4 Hz, 2H, C20-Ha), 4.20 (d, J = 8.5 Hz, 
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2H, C20-Hb), 4.10 (m, 4H, PEG-O-CH2-CH2-O-succinic) 3.51-3.80 (m, 
PEG backbone), 2.80 – 2.69 (m, 4H, PEG-COO-CH2-CH2-COO-PTX), 
2.64 (m, 4H, PEG-COO-CH2-CH2 -COO-PTX), 2.56 (m, 2H, C6-Ha), 
2.50 (d, J = 3.9 Hz, 2H, 7-OH), 2.44 (s, 6H, C4-OAc), 2.36 (dd, J = 
15.4, 9.3 Hz, 2H, C14-Ha), 2.23 (s, 6H, C10-OAc), 2.15 (dd, J = 15.4, 
8.9 Hz, 2H, C14-Hb), 1.98 (s, 6H, C18-Me), 1.86 (m, 2H, C6-Hb), 1.68 
(s, 6H, C19-Me), 1.24 (s, 6H, C17-Me), 1.13 (s, 6H, C16-Me). 
2.7 Solubility 
The solubility of the conjugates was estimated by adding increasing 
amounts of conjugates to 0.1 mL ultrapure water at room temperature 
until saturation (116, 118). Solubility was estimated by the weights 
added in 3 parallel experiments.     
2.8 Stability of conjugates in PBS, BAL and serum of mice 
The conjugates were dissolved in 5 mL PBS at pH 6.9 and pH 7.4 
respectively (final concentration of PTX 20 µg/mL). The solutions were 
incubated at 37 ℃ in a water bath with shaking. 200 µL samples were 
withdrawn at pre-determined time points. The samples were then 
diluted with acetonitrile and centrifuged at 15000×g for 10 min before 
High Performance Liquid Chromatography (HPLC) analysis.  
Female NMRI mice (6 to 8 week-old; Elevage Janvier, Le Genest-St-
Isle, France) were used to collect serum and bronchoalveolar lavage 
(BAL). Blood samples were collected from the orbital sinus of the mice. 
The blood samples were kept in the fridge (4 °C) overnight and 
centrifuged at 12000×g. The serum supernatant was then taken and 
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stored at -20 °C. BAL was performed after euthanizing the mice by 
cervical dislocation. One ml of HBSS was injected into the trachea and 
left for 15 s. 0.5 mL of the fluid was then withdrawn and re-injected into 
the lung. All the BAL liquid was removed from the lung afterwards. This 
procedure was repeated twice until a total of 3 mL HBSS was injected. 
The BAL was then centrifuged at 4500×g for 10 min to remove the 
cells. The supernatant was collected and stored at -20 °C. All 
experimental procedures were performed in compliance with 
guidelines of Institutional Animal Care and Use Committee of the 
Université catholique de Louvain (Permit number: 2012/UCL/MD/006). 
Animals were anesthetized before manipulation and efforts were 
made to minimize animal suffering.      
The 6 kDa and 20 kDa conjugates were dissolved in 200 µL BAL in 
Eppendorf tubes at the concentration of 50 µg/mL and 35 µg/mL (PTX 
equiv.). Conjugates were also dissolved in 40 µL serum at the same 
concentrations as above. All the samples were then incubated at 37 ℃. 
These tubes were taken out for analysis at different time points. 200 
µL acetonitrile were added into the samples which were then 
centrifuged at 15000×g for 10 min before HPLC analysis. The 
percentages of conjugates remaining in BAL or serum over time were 
calculated by comparing with the amount recovered at 0 hour. The 
degradation half-lives of the conjugates were calculated from time vs. 
residual amount curves by assuming first-order kinetics. HPLC was 
carried out using the Hewlett Packard series 1100 system (Agilent 
Technologies, Palo Alto, CA) using a reverse phase C18 column  
(NUCLEOSIL® 300-5 C18 · 5 µm particles · 300 Å pores, 
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250mm×4.6mm, MACHEREY-NAGEL GmbH & Co. KG, Düren, 
Germany). The mobile phase was acetonitrile and water eluted at 1 
mL/min using a gradient protocol as follows: a linear gradient from 
acetonitrile 40% to 60% for 20 minutes, a linear gradient from 
acetonitrile 60% to 40% for 5 minutes. Absorbance of the column 
effluent was monitored at 227 nm (116). A standard curve was 
established in the range of 5-100 µg/mL of PTX dissolved in 
acetonitrile (correlation coefficient of R2 = 0.9995, LOD = 1.52 µg/ml, 
LOQ = 5.01 µg/ml). Samples of 20 µL were injected. The areas under 
the peaks of conjugates and paclitaxel were monitored. The retention 
time of paclitaxel was 13 min according to this analytical method. PEG 
chain does not have a significant UV absorbance. After conjugation 
with paclitaxel, the PEG-PTX conjugates had retention times of 19-20 
min for 6k and 15-16 min for 20k. The peaks of the mono- and di-
conjugates were not separated in the method.    
2.9 Cytotoxicity  
The in vitro cytotoxicity of the conjugates was tested on LL/2 Lewis 
lung carcinoma cell line (ATCC® CRL-1642™) and B16-F10 melanoma 
cell line (ATCC® CRL-6475™) using the MTT assay. LL/2 cells were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM, Life 
Technologies, Belgium) and B16-F10 melanoma cells were cultured in 
Minimum Essential Medium Eagle Alpha (MEM Alpha, Life 
Technologies, Belgium). Both media were supplemented with 10% 
fetal bovine serum and 1% antibiotics (Pen Strep, Life Technologies, 
Belgium). The cells were maintained in a 5% CO2 humidified 
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atmosphere at 37 °C.  
Cells were seeded in 96 plates at a density of 100 cells/well for LL/2 
and 1000 cells/well for B16-F10. Cells were then incubated with the 4 
conjugates, and Taxol dissolved in 100 µL full culture medium at 
different concentrations (6×10-6-2.5 µg/mL, PTX equivalent) for 72 
hours. PTX was also tested at the same concentrations by diluting 
PTX stock solution in DMSO (500 µg/mL) with culture medium. Less 
than 0.5% of DMSO was present in the final culture medium. Then, 
the medium was removed and the cells were incubated with MTT 0.5 
mg/mL in culture medium without FBS for 3 hours. MTT was aspirated 
off and DMSO was added to dissolve the formazan crystal. The 
absorbance was then measured at 560 nm with the 
spectrophotometer Multiskan EX (Thermo Scientific, US). Untreated 
cells were taken as control with 100% metabolic activity and cells 
incubated with Triton X-100 1% were used as positive control. The 
toxicity of PEG reagents (PEG, PEG-N3 6 kDa and 20 kDa, PEG-suc 
6 kDa and 20 kDa) was evaluated on LL/2 cells at a concentration 
corresponding to 2.5 µg/mL PTX in the conjugates. Cremophor 
EL/ethanol was also tested on LL/2 cells at a concentration 
corresponding to 2.5 µg/mL PTX in Taxol. DMSO 0.5% in culture 
medium (corresponding to 2.5 ug/mL PTX) was tested on LL/2 cells 
as a control. The IC50 was calculated using the regression equation 
from the plot showing the cell metabolic activity versus the log of 
concentration.  
Statistics 
All the results were shown as mean ± standard deviation. Mann-
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Whitney test was conducted to demonstrate statistical differences (p 
< 0.05); IC50 values of cytotoxicity were calculated from the dose-
response signal curve by regression function with variable hill slopes. 
The Pearson correlation coefficient was calculated using the Excel 
function CORREL. Graphpad Prism as well as Microsoft Excel 2010 
were used for data processing.  
3. Results and discussion 
3.1 Chemistry 
PEG-N3-PTX conjugates 6 kDa and 20 kDa were obtained using “click” 
chemistry. PTX was first modified by pentynoic acid to obtain an alkyne 
group, while PEG was activated to PEG-azide by tosylation followed 
by azidation. DMF was chosen as the solvent because of the 
satisfactory solubility of PTX, PEG as well as copper bromide in this 
solvent. As shown in Fig. 15, C2’-H on PTX shifted from δ 4.8 (a, Fig. 
15) to δ 5.5 (a’, Fig. 15) in 1H NMR spectra, which indicates the 
formation of the ester bond.  
PEG-suc-PTX conjugates 6 kDa and 20 kDa were obtained using a 
typical method of esterification. First, succinic acid was added to the 
PEG backbone to introduce carboxyl groups and also to act as a 
spacer between PTX and PEG. PTX was then conjugated to PEG 
under the catalysts DIC/DMAP in DCM. As shown in Fig. 15, C2’-H 
shifted from δ 4.8 (a, Fig. 15) to δ 5.5 (a’’, Fig. 15). No downfield shift 
was observed in 1H-NMR for either of the C2 (i, Fig. 15) or C7 (e, Fig. 
15) protons in both PEG-N3-PTX and PEG-suc-PTX structures, which 
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indicates that PTX was conjugated to PEG on the C2’. Therefore, the 
data confirm that it was not necessary to protect the 7-OH and 1-OH 
on PTX because the steric hindrance makes these two hydroxyls not 
easy to access for esterification (119). On the contrary, if the goal was 
to modify the 7-OH, the protection of 2’-OH on the side chain of PTX 
would be necessary (120). The PTX substitution reached 90% for both 
structures at both molecular weights. 
The drug loading in the conjugates was calculated by dividing PTX 
mass by the whole molecule mass according to the ratio of PTX 
substitution calculated with 1H NMR. It reached 20% and 7% (w/w) in 
all the structures of 6 kDa and 20 kDa conjugates, respectively. The 
molecular ratio of PTX in PEG-PTX conjugates was approximately 1.8 
PTX for 1 PEG molecule in both structures and both molecular weights. 
The structure of the azide conjugate is novel with a hydrolysable ester 
bond and a stable triazole link between PEG and PTX. The ester bond 
ensures that paclitaxel can be released in an intact form and the 
triazole link enhances the stability of the conjugate. Although various 
polymer-paclitaxel conjugates have been prepared, few studies have 
been performed in the field of pulmonary drug delivery. In the case of 
the pulmonary delivery of polymer-drug conjugates, a long residence 
time of the conjugates in the lungs is crucial for attaining sustained 
local drug concentrations. Herein, we used high molecular weight PEG 
in the conjugates, with the expectation that it should contribute to a 
long drug residency in the lungs (99). Then, the progressive release 
of paclitaxel by hydrolysis of the ester bond should result in sustained 
local drug concentrations. 
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3.2 Aqueous solubility and in vitro stability of PEG-PTX 
conjugates 
The PEGylation of PTX greatly increased the aqueous solubility of 
PTX. The reported solubility of PTX in water in the literature is 0.5 
µg/mL. PEG-N3-PTX and PEG-suc-PTX 6 kDa conjugates showed a 
highly increased solubility of 30 mg/mL and 25 mg/mL PTX equivalent 
(i.e., 145 mg/mL and 118 mg/mL conjugates). Although PEG is a 
hydrophilic molecule, the solubilities of the 20 kDa conjugates were 
lower (73 mg/mL for PEG-N3-PTX 20 kDa and 61 mg/mL for PEG-suc-
PTX 20 kDa, or 5.8 mg/mL and 4.9 mg/mL PTX equivalent, 
respectively). Conjugation increased the solubility of paclitaxel in pure 
water by 3-4 orders of magnitude. The solvation of the PEG chain 
probably decreases with the increase of PEG molecular weight, due 
to the crystalline structure of the polymer chain. The lower solubility 
with higher PEG molecular weight was also found in previous reports 
on PEG-PTX prodrugs (80, 116). 
The in vitro stability tests were performed in PBS at pH 6.9 and 7.4, 
BAL and mouse serum. All the conjugates showed better stability in 
PBS pH 6.9 than in PBS pH 7.4. The pH of 6.9 is the pH of the lung 
lining fluid in humans (121), while the pH of 7.4 is the physiological pH 
of human blood. As shown in Table 3 and Fig.16, the half-lives of these 
conjugates were longer than 72 hours in PBS pH 6.9, but decreased 
significantly in BAL and serum. The PEG-N3-PTX conjugates were 
more stable than the PEG-suc-PTX conjugates. In our strategy, PEG-
N3-PTX was designed due to the superiority of the stability of the 
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triazole ring over the ester bond. The triazole ring is very stable and 
could not hydrolyze before the ester bond. Thus, free PTX will be 
released from the conjugate in an active form. However, there are two 
ester bonds between PTX and PEG in the structure of PEG-suc-PTX, 
which leads to increased possibilities for hydrolysis. As a result, the 
stability of the PEG-N3-PTX conjugates should increase compared 
with the PEG-suc-PTX conjugates, which is consistent with the results 
obtained.  
 
Table 3. Half-lives of conjugates in different media 
Conjugates t ½ PBS 
pH 6.9 (h) 
t ½ PBS 
pH 7.4 (h) 
t½ BAL 
(h) 
t ½ Serum 
(h) 
PEG-N3-PTX 6k >72 >72 8.6±1.1 3.2±0.8 
PEG-N3-PTX 20k >72 >72 7.2±1.0 3.5±0.6 
PEG-suc-PTX 6k >72 10.0±2.5* 2.5±0.1* 1.1±0.2* 
PEG-suc-PTX 20k >72 36.1±4.1 4.0±0.4 1.0±0.1 
  Means ± SD are given, n=3. * p<0.05, PEG-suc-PTX 6k versus 20k           
  (Mann-Whitney). 
 
In BAL and PBS pH 7.4, the 20 kDa succinic conjugate presented 
longer half-life than the 6 kDa (p < 0.05 Mann-Whitney). However, for 
the azide conjugates, increased stability was not observed for the 20 
kDa conjugate. In serum, all conjugates had short half-lives. The PEG-
N3-PTX azide conjugates showed better stability than the PEG-suc-
PTX succinic conjugates at both MW in serum. Both 6 kDa and 20 kDa 
molecular weights of conjugates presented similar stability in serum 
for both structures. Although in the literature, the hydrolysis rate of 
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conjugates does not correlate with MW (80, 113, 116), the stability of 
PEG-suc-PTX conjugates at pH 7.4 and in BAL was dependent on MW 
in our study. The increased stability of the 20 kDa PEG-suc-PTX might 
result from the increased steric hindrance created by PEG and thereby, 
decreased accessibility of esterase for hydrolysis.  
 
 
Fig. 16 Stability profiles of conjugates in bronchoalveolar lavage (A) and 
serum of mouse (B). 
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3.3 Cytotoxicity 
The cytotoxicity of the conjugates was evaluated on LL/2 Lewis lung 
carcinoma cells and B16-F10 melanoma cells, which are widely used 
cell lines to establish a lung cancer model or a lung metastasis model 
in mice (122-124). The conjugates and Taxol were incubated at 37 °C 
with the cells for 72 hours in order to provide enough time for PTX 
release. Free PTX was also tested as a control. All the conjugates 
showed cytotoxicity on both cell lines but lower than Taxol and free 
PTX. Taxol had a similar cytotoxic profile as free PTX but with higher 
IC50. The IC50 of all the conjugates were 5-fold higher compared with 
Taxol and more than 7-fold higher compared with free PTX (Table 4, 
Fig. 17). This is likely due to the slow release of PTX from the 
conjugates. However, the statistical test was not able to show a 
correlation between the in vitro release of the four conjugates in all the 
media tested and the cytotoxicity (Pearson correlation, p > 0.05 for all). 
The sensitivity of these two cell lines to PTX cannot be compared 
because the numbers of cells seeded were different in the tests in 
order to reach the linear detection range of the UV absorbance.  
The cellular internalization process is supposed to be different for free 
paclitaxel and Taxol, which comprises nanomicelles. Taxol showed a 
slightly increased IC50 value compared with free paclitaxel. In the case 
of the 4 conjugates, as molecular mass of conjugates increased, the 
cellular internalization likely involved endocytosis instead of diffusion 
of free PTX. This change of mechanism along with the slow release of 
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PTX from the conjugates might lead to the increase of IC50. An 
increase of the IC50 after conjugation of anti-cancer drugs to polymers 
has previously been reported (113). PTX was turned to a prodrug by 
PEGylation at the 2’-OH which is a necessary group for cytotoxicity 
(125). Thus the prodrug temporally lost cytotoxicity. After the 
hydrolysis of the ester bond between PTX and PEG, PTX was 
released in a non-conjugated form and began to interfere with the cell 
cycle and led to cell death.    
 
Table 4. IC 50 values of all the conjugates calculated based on the data of 
MTT test 
IC50 of conjugates on different cancer cells (µg/mL PTX equiv.) 
 LL/2 B16-F10 
PEG-N3-PTX 6k 0.0203 ± 0.0064 * 0.0567 ± 0.0110 * 
PEG-N3-PTX 20k 0.0286 ± 0.0058 * 0.0521 ± 0.0134 * 
PEG-suc-PTX 6k 0.1789 ± 0.0551 * 0.3050 ± 0.0363 * 
PEG-suc-PTX 20k 0.0226 ± 0.0039 * 0.0809 ± 0.0083 * 
Taxol 
PTX 
0.0039 ± 0.0006 * 
   0.0022 ± 0.0005 
0.0100 ± 0.0005 * 
   0.0069 ± 0.0009 
Means ± SD are given, n=3, 8 measurements each test. * p<0.05, conjugates or 
Taxol versus PTX group, respectively (Mann-Whitney). 
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Fig. 17 Cell metabolic activities of PEG-PTX conjugates and Taxol on LL/2 
Lewis lung cancer cells (A) and B16-F10 melanoma cells (B). Results are 
shown as the mean of 3 independent tests (8 measurements each test) and 
standard deviation. 
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We assessed the cytotoxicity of the PEG reagents, PEG-suc and 
PEG-N3, on LL/2 cells because as PTX was released, PEG reagents 
were simultaneously released. The results showed that all the PEG 
reagents were very slightly toxic to LL/2 cells at the concentration of 
2.5 µg/mL (PTX equiv.; Fig. 18), which was the highest concentration 
used in the cytotoxicity assay for LL/2 cells (Fig. 17). In particular, 
PEG-suc 20k was slightly toxic to LL/2 cells, with a 15% loss of viability 
after 72h of contact. In Taxol, paclitaxel is dissolved in Cremophor EL 
and ethanol (1:1 v/v). Because Cremophor EL is involved in the side 
effects induced by Taxol, we also tested the cytotoxicity of Cremophor 
EL with ethanol on LL/2 cells. Results showed that Cremophor EL did 
not inhibit the growth of LL/2 cells at the concentration of 2.5 µg/mL 
(PTX equiv.; Fig. 18). This could come from the low concentration of 
Cremophor EL tested. Therefore, the decrease in cell viability induced 
by Taxol (Fig. 17) was caused by paclitaxel itself, and not the 
excipients Cremophor EL and ethanol. To exclude the interference of 
DMSO used in the stock solution of free PTX, the cytotoxicity of 0.5% 
DMSO was also tested on LL/2 cells. This amount of DMSO in culture 
medium was corresponded to the highest PTX concentration 2.5 
µg/mL used in this test. Results showed DMSO below this level did not 
interfere with the cell viability (Fig.18).  
To have an idea of the PTX concentrations in the cell culture medium 
after 72h of incubation of the conjugates, we extracted PTX from the 
supernatant of the incubation medium of PEG-N3-PTX 6 kDa (200 
µg/mL PTX equiv.) and assayed it by HPLC. We found that the 
concentration of PTX was 23 ± 4 µg/mL, which is only 12 % of the total 
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amount of PTX in the conjugate. In addition, there was only 11% of 
intact PEG-N3-PTX 6 kDa conjugate remaining in the incubation 
medium. The low level of PTX detected may be due to the uptake and 
metabolism of PTX by the cells. We suggest that the conjugates were 
taken up by the cells through endocytosis and then that PTX was 
released in the cytoplasm and had its cytotoxic effect. This hypothesis 
might explain the lack of correlation between cytotoxicity and drug 
release in acellular media. On the other hand, a study in the literature 
investigated the intracellular fate of polymer-bound anticancer agents 
and showed that the toxicity of conjugates might appear against the 
cytoplasmic, endosomal or lysosomal membranes. Then, the 
disintegration of the cell organization preceded apoptosis (126). 
Therefore, conjugates themselves could present cytotoxicity without 
the release of the anticancer drug. In the case of our PEG-PTX 
conjugates, the results imply that the toxicity of the conjugates was 
mainly caused by the released PTX or the conjugates themselves, but 
not by the PEG reagents.  
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Fig. 18 Cytotoxicity of PEG reagents on LL/2 cells after 72 hour incubation 
at the concentration of 2.5 µg/mL (PTX equiv.). Results are shown as the 
mean of 3 independent tests (8 measurements per test) and standard 
deviation.  * p<0.05, when compared with control group. # p<0.05, when 
compared with triton 1% (Mann-Whitney). 
 
4. Conclusion 
Two structures of PEG-PTX conjugates with ester bond as linkage 
have been produced. Large PEGs with MW of 6 kDa and 20 kDa have 
been employed for the purpose of sustaining the presence of PTX in 
the lungs. The conjugates developed by click chemistry demonstrated 
good stability at the pH of the lung lining fluid and in murine BAL, which 
is essential for sustaining drug release in the lungs. In vitro cytotoxicity 
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studies on two types of cancer cells showed that the IC50 of all the 
conjugates were increased due to the formation of the prodrugs at 2’-
OH on PTX. To conclude, the delivery system of PEG-PTX conjugates 
shows the potential to sustain the release of PTX in the lungs. The 
sustained drug release and the anti-tumor efficacy of the conjugates 
are currently investigated in vivo in the Lewis lung cancer murine 
model. If efficacy and safety are demonstrated in animal models, these 
conjugates could possibly be administrated to patients using a 
nebulizer and a mouthpiece in a cytotoxic chamber in the hospital in 
preliminary clinical trials. 
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ABSTRACT  
Pulmonary delivery offers an attractive route of administration for 
chemotherapeutic agents, with the advantages of high drug 
concentrations locally and low side effects systemically. However, fast 
clearance mechanisms result in short residence time of small 
molecule drugs in the lungs. Moreover, the local toxicity induced by 
antineoplastic drugs is considered a major obstacle for the clinical 
application of inhaled chemotherapy. In this study, we explored the 
utility of 6 kDa and 20 kDa polyethylene glycol-paclitaxel (PEG-PTX) 
conjugates to retain paclitaxel within the lungs, achieve its sustained 
release locally, and thereby, improve its efficacy and reduce its 
pulmonary toxicity. The conjugates increased the maximum tolerated 
dose of paclitaxel by up to 100-fold following intratracheal instillation 
in healthy mice. PEG-PTX conjugates induced lung inflammation. 
However, the inflammation was lower than that induced by an 
equivalent dose of the free drug and it was reversible. Conjugation of 
paclitaxel to both PEG sizes significantly enhanced its anti-tumor 
efficacy following intratracheal instillation of a single dose in a Lewis 
lung carcinoma model in mice. PEG-PTX 20k showed equivalent 
efficacy as PEG-PTX 6k delivered at a 2.5-fold higher dose, 
suggesting that the molecular weight of the conjugate plays a role in 
anti-cancer activity. PEG-PTX 20k conjugate presented a prolonged 
residency and a sustained paclitaxel release within the lungs. This 
study showed that PEGylation of paclitaxel offers a potential delivery 
system for inhalation with improved anti-cancer efficacy, prolonged 
exposure of lung-resident tumors to the antineoplastic drug and 
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reduced local toxicity.  
 
Adapted from: PEGylation of paclitaxel largely decreases toxicity and increases anti-
tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma (in 
revision)  
Authors: Tian Luo, Cristina Loira-Pastoriza, Harshad P. Patil, Bernard Ucakar, Giulio 
Muccioli, Cynthia Bosquillon, Rita Vanbever 
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1. Introduction 
Lung cancer is the leading cause of cancer-related death worldwide 
(127). Chemotherapy is widely used to treat lung cancer either alone 
or, combined with surgical resection and radiotherapy (128). However 
the 5-year survival rate only reaches 17% (129). The poor efficacy of 
the treatments results from the late diagnosis and from the limited and 
nonspecific access of chemotherapeutics to lung tumors after 
intravenous administration (14, 130). Pulmonary delivery is 
considered an attractive route of administration for chemotherapeutic 
agents, with the advantages of direct drug deposition at the diseased 
site and low systemic side effects. However, it is challenging to 
achieve sustained drug concentrations locally because of the efficient 
clearance mechanisms in the lungs. Small molecules are absorbed in 
the bloodstream within minutes and this results in a short residence 
time of chemotherapeutics in the lungs (45). Moreover, safety issue 
remains a major consideration for inhaled chemotherapeutics. The 
inhalation of cytotoxic drugs may cause transient high local drug 
concentrations, which may lead to toxicity to the lung tissue (47, 94, 
131). Therefore, the benefits and the challenges of inhaled 
chemotherapy have stimulated interests in developing delivery 
systems for retaining and progressively releasing anti-cancer drugs in 
the lungs (32, 97).  
Polymer-drug conjugates are prodrug systems with one or more drug 
molecules covalently conjugated to a hydrophilic polymer. They can 
offer sustained release of drugs and reduced toxicity. Polymer-drug 
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conjugates of anti-cancer agents have been extensively studied 
following intravenous administration. The enhanced permeability and 
retention (EPR) effect favors the passive accumulation of anticancer 
agents into the tumor tissue when delivered intravenously (132).  In 
general, drugs are conjugated to polymers with biodegradable linkers, 
which allow the release of the active therapeutics. Conjugates 
containing ester or amide bonds can be hydrolyzed by non-specific 
esterase in extracellular environment or within cellular lysosomes.  
As an alternative to inhalation of free drug formulations, polymer-drug 
conjugates would theoretically offer prolonged retention time of 
anticancer agents in the lungs and reduced toxicity to the lung tissue. 
In contrast to small molecules, macromolecules present  long 
residence times in the airspaces (45). However, the pulmonary 
delivery of polymer-drug conjugates in lung cancer has not been 
thoroughly investigated. Studies on the pulmonary administration of 
poly-L-glutamic acid paclitaxel conjugate (PGA-PTX) and doxorubicin-
conjugated dendrimers have been reported (111, 112, 133). These 
studies performed in animal lung cancer models showed that polymer-
drug conjugates offer potential to improve the tumor exposure to the 
cytotoxic drug and to provide better tolerance locally.   
Large hydrophilic polymers such as polyethylene glycol (PEG) 
improve the solubility of hydrophobic therapeutics but also increase 
retention times in the lungs. PEG with large molecular weight (MW > 
5 kDa) can be retained in the lungs for up to 7 days (46). This feature 
could favour the sustained release of drugs conjugated to PEG in the 
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lungs. Moreover, PEG is nontoxic and it can be eliminated by renal 
and hepatic pathways. It has already been approved for human use in 
dosage forms for intravenous, oral and pulmonary applications. In 
addition, conjugates have relatively high drug loading (10-30%) 
compared with nanocarrier systems (134). There are various studies 
about PEGylated anti-cancer drugs by the intravenous route. 
PEGylated irinotecan, docetaxel, and SN38 (SN 38, 7-ethyl-10-
hydroxy-camptothecin) are under phase II or III clinical trials by the 
intravenous route for the treatment of solid tumors (20, 73, 79). 
However, the application of PEGylated chemotherapeutics in lung 
cancer using pulmonary delivery has not been investigated.   
Paclitaxel (PTX) has been widely used to treat non-small cell lung 
cancer. The commercial product is Taxol, which contains the water-
insoluble paclitaxel formulated with Cremophor EL and dehydrated 
alcohol (135). The treatment is currently administered by intravenous 
infusion in the clinic. However, significant adverse effects such as 
hypersensitivity reactions, hematologic, neuro toxicities have been 
reported and some are not only related to paclitaxel but also to 
Cremophor EL in the formulation (136, 137). In addition, the oily nature 
of Cremophor will hamper its administration to the lungs. Therefore,   
developing drug delivery systems for inhaled paclitaxel without using 
Cremophor EL as solubilizer is critical.  
In this study, we explored the possibility of using polyethylene glycol-
paclitaxel (PEG-PTX) conjugates for inhaled chemotherapy and 
assessed the safety and efficacy of their pulmonary administration in 
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vivo in mice. PEG-PTX conjugates with PEG molecular weights of 6 
kDa and 20 kDa have previously been produced and characterized in 
vitro (138). The conjugates were synthesized by “click” chemistry and 
contained hydrolysable ester bonds between PTX and PEG.  As the 
hydrolysis of the ester bonds by non-specific esterase proceeds, PTX 
is released in an active form. The in vitro data showed that PEG-PTX 
conjugates at both molecular weights were stable in phosphate buffer 
saline (half-life ≥72 h) and bronchoalveolar lavage (half-life of 7 to 9 
h). The conjugates presented cytotoxicity to B16-F10 melanoma cells 
and LL/2 Lewis lung cancer cells in vitro, but less than Taxol. These 
data suggests that PEG-PTX conjugates have the potential to prolong 
the retention time of paclitaxel in the lungs. The prodrug nature of 
PEG-PTX conjugates is expected to reduce the local toxicity 
compared with the native drug. Therefore, we hypothesized that PEG-
PTX conjugates delivered to the lungs would show improved antitumor 
efficacy with reduced toxicity in vivo.  
2. Materials and methods 
2.1 Materials  
PTX was purchased from Chemieliva (Chongqing, China). PEG 6 kDa 
and 20 kDa were purchased from Iris Biotech (Marktredwitz, 
Germany). Taxol was obtained from Brystol-Myers Squibb. Hanks 
balanced salt solution (HBSS), phosphate buffered saline (PBS), 
Dulbecco’s modified Eagle’s medium (DMEM), penicillin/streptomycin 
(Pen Strep), and fetal bovine serum (FBS) were obtained from Life 
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Technologies (Belgium). Cell culture flasks and microplates were from 
Corning (Corning® T-75, Sigma-Aldrich, USA). Tissue-Tek® O.C.T. 
Compound and Cryomold were purchased from Sakura® Finetek 
(Torrance, CA). Superfrost TM microscope slides and blot were 
obtained from Gerhard Menzel B.V. & Co.KG (Braunschweig, 
Germany). Pierce micro BCA protein assay kit and Pierce lactate 
dehydrogenase (LDH) cytotoxicity assay kit were from Thermo Fisher 
Scientific (Leuven, Belgium). ONE-glo® luciferase assay kit was 
purchased from Promega (Leiden, Netherlands). HPLC grade 
acetonitrile was from Merck (Darmstadt, Germany). Ultrapure water 
was used throughout and all other reagents were of analytical grade. 
2.2 PEG-PTX conjugates and Taxol 
PEG-PTX conjugates made of linear PEG 6 kDa or 20 kDa were 
prepared by conjugating paclitaxel to PEG at both its hydroxyl ends 
via click chemistry using azide linker triazole rings and ester bonds, as 
previously described (138). The conjugates were white lyophilized 
powders and the solutions of conjugates were filtrated through 0.22 
μm membrane before lyophilisation. 6k and 20k PEG-PTX conjugates 
were reconstituted in 37 °C sterile PBS according to the desired doses 
before administration to mice. Taxol is the commercial formulation of 
paclitaxel, which is made of 6 mg paclitaxel, 50% of Cremophor EL 
and 50% of ethanol per mL. Taxol was diluted with sterile PBS 
according to the desired doses and filtrated through 0.22 μm 
membrane before administration to mice.  
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2.3 Animals 
Female C57BL/6NJR mice (6 to 8 weeks old, Janvier, Le Genest-
StIsle, France) were kept on a 12-hour light-dark cycle and were 
allowed to food and water ad libitum. The experimental protocols were 
approved by the Institutional Animal Care and Use Committee of the 
Université catholique de Louvain (Permit number: 2012/UCL/MD/006). 
All studies were performed under anesthesia and all efforts were made 
to minimize animal suffering. 
Mice were anesthetized by intraperitoneal injection of 
ketamine/xylazine (90/10 mg/kg) before receiving paclitaxel 
formulations by intratracheal instillation (i.t.). The mouse was fixed to 
make sure its neck was vertical. After gently pulling the tongue out, 
treatment solution was pipetted on the top of trachea. The tongue was 
released after two breaths were completed. Single dose treatments of 
the different formulations were given in a volume of 50 μL per mouse. 
Blood samples were collected from the orbital sinus and kept at 4 °C 
overnight. After centrifugation at 12,000×g for 10 min, the serum was 
withdrawn and stored at -20 °C. Bronchoalveolar lavage (BAL) was 
performed after euthanizing the mice by cervical dislocation. One ml 
of HBSS was injected into the trachea and left for 15 s. 0.5 mL of the 
fluid was then withdrawn and re-injected into the lungs. All the BAL 
liquid was removed from the lungs afterwards. The volume of 
recovered BAL was recorded. The BAL samples were then centrifuged 
at 4,500×g for 10 min to remove the cells. The supernatants were 
collected and stored at -20 °C.  The lungs were then resected and 
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kept in 0.5 mL HBSS on ice during the experiment. The lungs were 
homogenized and centrifuged at 3000×g rpm for 10 min. The 
supernatants were withdrawn and stored at -20 °C.  
2.4 Maximum tolerated doses of PEG-PTX conjugates delivered 
intratracheally 
To determine the toxicity of PEG-PTX conjugates, the maximum 
tolerated doses (MTD) of PEG-PTX conjugates and Taxol were 
assessed following intratracheal instillation in female healthy 
C57BL/6NJR mice by the method describing at 2.3. PEG-PTX 6k 
conjugate was delivered by intratracheal instillation at doses of 10, 25, 
and 50 mg/kg (PTX equiv.). PEG-PTX 20k conjugate was delivered by 
intratracheal instillation at the dose of 20 mg/kg (PTX equiv.). Taxol 
was delivered by intratracheal instillation at doses of 0.5, 1.2, 2, 5 
mg/kg. Taxol was also injected in the tail vein at doses of 10 mg/kg 
and 20 mg/kg in 200 µL. Mice were observed for 2 weeks. Symptoms 
and the numbers of surviving mice were recorded. The appropriate 
endpoints were defined based on signs of moderate severity, as 
described in the guidance from the Laboratory Animal Science 
Association. The MTD was defined as a maximum body weight loss of 
20% and neither death nor severe symptoms occurrence within 2 
weeks.  
2.5 Local toxicity of PEG-PTX conjugates in the lungs 
The local toxicity of the PEG-PTX conjugates and Taxol were 
assessed in healthy female C57BL/6NJR mice 24 hours, 72 hours and 
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7 days post intratracheal instillation. PEG-PTX 6k, 20k conjugates and 
Taxol were delivered by intratracheal instillation in 50 μL at their MTDs, 
i.e., 50 mg/kg, 20 mg/kg, and 0.5 mg/kg, respectively. The local toxicity 
of PEG-N3 6k was also investigated at the equivalent dose of 50 mg/kg 
PTX. In addition, a low dose of PEG-PTX 6k of 0.5 mg/kg was also 
assessed 24 hours post intratracheal delivery.  Mice were sacrificed 
at the predetermined time points and about 1 mL bronchoalveolar 
lavage was recovered and centrifuged immediately according to the 
procedures described in 2.3. Total protein and lactate dehydrogenase 
(LDH) in BAL supernatant were analyzed by Pierce BCA protein assay 
kit and LDH assay kit, respectively. Cell pellets were reconstituted at 
a concentration of 20,000 cells/mL and total live cells were counted by 
Türk’s solution method (Merck KGaA, Darmstadt, Germany). The 
differential cell counts were obtained by cytocentrifugation and 
coloration with Diff Quick® (Medion Diagnostics AG, Switzerland). 
The lungs were inflated with 1 mL Tissue Tek/PBS (1:1) and carefully 
removed from mice. The left lobes were embedded into Tissue Tek 
cryomatrix and then placed into liquid nitrogen to freeze rapidly. 
Frozen sections (10 μm) were performed with Cryostat (Leica 
Microsystems, Wetzlar, GE) and stained with haematoxylin-eosin 
(Sakura DRS 601). The sections were examined by Leica slide 
scanner SCN 400 (Leica Biosystems, Wetzlar, GE).   
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2.6 Anti-tumor efficacy of PEG-PTX conjugates against Lewis 
lung carcinoma  
Murine Lewis Lung Carcinoma cell line (LL/2-luc-M38 Bioware Cell 
Line, Caliper Life Sciences, Inc) stably expressing luciferase was a gift 
from Prof. Didier Cataldo, University of Liege (Belgium). LL/2-luc-M38 
was cultured at 37 °C in 5% CO2, in DMEM supplemented with 10% 
FBS, 1 mM sodium pyruvate and 1% Pen Strep. 
C57BL/6NJR female mice were randomly assigned to 5 groups 
according to treatments (n=6). A Lewis lung carcinoma model was 
established by tail vein injection of Lewis Lung carcinoma cells. On 
day 0, each C57BL/6NJR female mouse received 2×105 cells 
(passage 17 or 18) in 0.1 mL PBS intravenously (i.v.). On day 7, single 
dose treatments of PEG-PTX 6k, 20k conjugates and Taxol were 
delivered to 3 groups of mice by intratracheal instillation in 50 μL at 
their MTD, i.e., 50 mg/kg, 20 mg/kg, and 0.5 mg/kg, respectively. The 
preparation of the conjugates and Taxol solutions followed the 
procedure described in 2.2. 50 μL PBS was administered 
intratracheally to one group of mice as a control. In addition, one group 
of mice received 20 mg/kg of Taxol in 200 μL by tail vein injection to 
compare the efficacy of different administration routes. Mice were 
observed for symptoms and body weights were recorded. On day 14, 
all mice were euthanized by cervical dislocation. The lungs were 
immediately taken. Lung weights were recorded. The number of lung 
metastases were counted using bioluminescence on total resected 
and grounded lungs. One glo® assay was conducted to detect 
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bioluminescence and LL/2-luc-M38 cells cultured in vitro were used as 
calibration.  
2.7 Kinetics of in vivo distribution in the respiratory tract  
PEG-PTX 20k and Taxol were investigated for their release kinetics 
and biodistribution in vivo. Female C57BL/6NJR mice were 
anesthetized by ketamine/xylazine (90/10 mg/kg) intraperitoneal 
injection. PEG-PTX 20k conjugates and Taxol were delivered by 
intratracheal instillation in 50 μL at their MTD, i.e., 20 mg/kg and 0.5 
mg/kg, respectively. Blood was taken immediately after administration 
of treatments. Mice were then euthanized. This time point was marked 
as 0h. 1 mL BAL and lungs were taken according to the procedure 
described in 2.3.   Blood, BAL and lungs were also collected 24h and 
48h post intratracheal instillation. To extract paclitaxel from serum, 
BAL and suspensions of homogenized lungs, acetonitrile was added 
at 1:1 (v/v) ratio to the samples and vortexed for 15 seconds. The 
suspensions were then centrifuged at 10,000×g for 10 min and the 
supernatants were withdrawn. The supernatants were then dried 
under nitrogen flow at room temperature. The resulting residues from 
blood samples were reconstituted in 100 μL water/acetonitrile (1:1 v/v). 
The residues from BAL and lung samples were reconstituted in 300 μL 
water/acetonitrile (1:1 v/v). The samples were then centrifuged 
(10000×g, 10 min) and 20 µL of the supernatant were analyzed by 
HPLC-MS (for PTX analysis) or by HPLC-UV (for analysis of the 
remaining PEG-PTX conjugates) by UV absorbance. The use of 
HPLC-UV for the analysis of PEG-PTX 20k was necessary because 
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of the lack of proper signal for this large molecule with the LC-MS used 
in this study.  
Briefly, Paclitaxel was analyzed by LC-MS using an LTQ-Orbitrap 
mass spectrometer coupled to an Accela HPLC system (Thermo 
Fischer Scientific). Analytic separation was achieved using reverse 
phase C18 column (LiChrospher 100 RP-18 5 µm particles, 250 x 4 
mm, Merck, Darmstadt, Germany). Mobile phases A and B consisted 
of H2O / formic acid 99.9:0.1 (v/v) and acetonitrile. The gradient (1 
mL/min) was performed as follows: starting at 40% B and reaching 
linearly 90% B in 13 min. This was followed by 7 min at 90% B before 
equilibrating at 40% B. An ESI source operated in the positive mode 
was used for the MS analysis. The ESI spray voltage was set at 5.0 
kV and the capillary temperature at 275°C while the sheath gas flow 
and auxiliary gas flow were set at 20 and 10 arbitrary units, 
respectively. Paclitaxel was analyzed as the [M+H]+ ion (m/z 
854.33823). A standard curve was established in the range of 0.1-50 
μg/mL of PTX in BAL following the extraction method above 
(correlation coefficient R= 0.9999, LOD = 0.13 µg/ml, LOQ = 0.44 
µg/ml, recovery at 10 μg/mL was 99.6%). Standard curves were also 
established in homogenized mouse lung suspension and mouse 
serum in the range of 0.1-10 μg/mL of PTX following the same 
extraction method above (R = 0.9948 and 0.9994, recovery at 10 
μg/mL was 101.1% and 93.5% in lungs and serum, respectively).   
HPLC was carried out using the Hewlett Packard series 1100 system 
(Agilent Technologies, Palo Alto, CA) with a reverse phase C18 
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column  (NUCLEOSIL® 300-5 C18 · 5 µm particles · 300 Å pores, 
250mm×4.6mm, MACHEREY-NAGEL GmbH & Co. KG, Düren, 
Germany). The mobile phase was acetonitrile and water eluted at 1 
mL/min using a gradient protocol as follows: a linear gradient from 
acetonitrile 40% to 60% for 20 minutes, a linear gradient from 
acetonitrile 60% to 40% for 5 minutes. Absorbance of the column 
effluent was monitored at 227 nm. The areas under the peaks of 
conjugates were monitored.   
2.8 Statistics 
Results were shown as mean ± standard error of the mean (SEM). 
Mann-Whitney test was performed using the software GraphPad 
Prism to demonstrate statistical differences (p < 0.05) between groups.   
3. Results 
3.1 Conjugation to PEG increased the MTD of paclitaxel post-
intratracheal delivery 
An acute toxicity study was conducted to assess the MTD of the PEG-
PTX conjugates following intratracheal instillation. The maximum 
doses tested were 50 mg/kg and 20 mg/kg for PEG-PTX 6k and 20k 
conjugate, respectively, because these doses reached the limits of 
their solubility in PBS. As controls, the MTD of Taxol was assessed 
following intratracheal instillation and intravenous injection.  
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All the intratracheal instillation groups showed body weight loss 1-2 
days post-delivery (Fig. 19A, B and C). A maximum of 7% of body 
weight loss was found in the group of PEG-PTX 6k 50 mg/kg (PTX 
equiv.) 1 day post-delivery. A maximum of 14% of body weight loss 
was found in the group of PEG-PTX 20k 20 mg/kg (PTX equiv.) at 2 
days post-delivery. However, these weight losses were reversible. All 
mice from the conjugate groups and Taxol 0.5 mg/kg group recovered 
their initial body weights within 3-4 days post-delivery.  
Subdued behavior, lung noises and hunching were found in the groups 
of PEG-PTX 6k 50 mg/kg (PTX equiv.), PEG-PTX 20k 20 mg/kg (PTX 
equiv.) as well as in the group receiving Taxol 0.5 mg/kg. However, 
these symptoms disappeared after 4-5 days of delivery. Death was 
found immediately after delivery in the group receiving Taxol 5 mg/kg 
intratracheally. The mice receiving Taxol 2 mg/kg and 1.2 mg/kg 
intratracheally survived for 1 day and 2 days post-delivery, respectively. 
Death was then found on the second and third days post-delivery.  
Mice were found to have tremors, lung noises, subdued behavior as 
well as hunching in the groups receiving Taxol 1.2 mg/kg and above. 
The dead mice of the group receiving Taxol 1.2 mg/kg were examined 
and lung haemorrhage was found. Therefore, the MTDs of PEG-PTX 
6k and 20k following intratracheal instillation were 50 mg/kg (PTX 
equiv.) and 20 mg/kg (PTX equiv.), respectively (Table 5). These 
values were 100-fold and 40-fold the MTD of Taxol, i.e., 0.5 mg/kg.    
The MTD of Taxol delivered by intravenous injection was also studied. 
Based on the reports in the literature (134, 139), two doses of 10 
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mg/kg and 20 mg/kg were delivered. Both groups of mice were found 
to have transient prostration for 5-10 minutes. The body weights of the 
2 groups stably increased for 2 weeks. Therefore, the MTD of Taxol 
following intravenous injection was 20 mg/kg in this study.   
 
Fig. 19 Body weights of mice receiving PEG-PTX conjugates and Taxol 
intratracheally and intravenously. (A) PEG-PTX 6k conjugate delivered 
intratracheally at different doses, (B) PEG-PTX 20k conjugate delivered 
intratracheally, (C) Taxol delivered intratracheally at different doses, (D) Taxol 
delivered intravenously at different doses. Mean ± SEM are shown, n=6 mice 
per group. 
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Table 5. MTD of PEG-paclitaxel conjugates and Taxol post i.t. or i.v. injection. 
MTD (PTX equiv.) 
PEG-PTX 6k i.t.  >50 mg/kg 
PEG-PTX 20k i.t. >20 mg/kg 
Taxol i.t. 0.5 mg/kg 
Taxol i.v. 20 mg/kg 
       n=6 mice per group 
 
3.2 Local toxicity studies of PEG-PTX conjugates in the lungs  
The local toxicity of the PEG-PTX conjugates to the lungs was 
assessed in healthy female C57BL/6NJR mice. Conjugates and Taxol 
were administered at their MTDs. PEG-N3 6k was the synthetic 
material of PEG-PTX 6k. It was tested to verify PEG toxicity to the lung 
tissue. We also tested Cremophor EL at the corresponding dose of 0.5 
mg/kg PTX, which would give a better understanding of the pulmonary 
toxicity of Taxol.   
We analyzed biochemical inflammation markers in BAL in order to 
check if PEG-PTX induced inflammation in the lungs. Total protein was 
analyzed to detect the alteration of the alveolar-capillary barrier. 
Results showed that the groups of Taxol 0.5 mg/kg, PEG-PTX 6k 50 
mg/kg (PTX equiv.), PEG-PTX 20k 20 mg/kg (PTX equiv.) and 
Cremophor EL 0.5 mg/kg (PTX equiv.) induced large increases of total 
protein levels at 24h and 72h.  However, PEG-PTX 6k at a lower dose 
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of 0.5 mg/kg (PTX equiv.) and PEG-N3 6k 50 mg/kg (PTX equiv.) did 
not induce an increase of total protein levels.  At Day 7, the total 
protein concentrations decreased to the normal levels in the groups of 
Taxol, PEG-PTX 6k and 20k (Fig. 20A). 
The extracellular presence of lactate dehydrogenase (LDH), an 
intracellular enzyme, can reflect injury to pulmonary cells. Taxol 0.5 
mg/kg increased LDH levels in bronchoalveolar lavage 24h after i.t. 
delivery (Fig. 20B). Cremophor EL delivered i.t. at the corresponding 
dose of 0.5 mg/kg paclitaxel also showed a significant increase of LDH 
level. PEG-PTX 6k and 20k at their MTD caused significant increases 
of LDH in BAL 24h post i.t. delivery. However, PEG-N3 6k delivered at 
the equiv. dose of PEG-PTX 6k 50 mg/kg (PTX equiv.) did not increase 
LDH level significantly. The LDH level of PEG-PTX 6k at a low dose of 
0.5 mg/kg, which was the MTD of Taxol i.t., remained at the same level 
as the control. At Day 7, the LDH concentration decreased to the 
normal level in the groups of Taxol, PEG-PTX 20k, and PEG-N3 6k. 
The group of PEG-PTX 6k 50 mg/kg (PTX equiv.) showed decreased 
LDH concentration compared with 24h and 72h, but it still had higher  
LDH level than the PBS control group.  
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Fig. 20 Local toxicity of PEG-PTX conjugates, Taxol, free PEG-N3 6k and 
Cremophor EL. (A) Total protein (B) LDH level (C) total cell numbers  (D) 
macrophage numbers (E) neutrophil numbers and (F) lymphocyte numbers 
in BAL at different time points post intratracheal instillation of PEG-PTX 
conjugates, Taxol, PEG-N3 6k and Cremophor EL.  Mean and SEM are 
shown, n=4-6 mice per group, * p< 0.05, ** p< 0.01, compared with control 
group (Mann-Whitney).  
CHAPTER 3. PEGYLATION OF PACLITAXEL LARGELY IMPROVES ITS SAFETY AND 
ANTI-TUMOR EFFICACY FOLLOWING PULMONARY DELIVERY IN A MOUSE MODEL 
OF LUNG CARCINOMA 
 
  92 
 
Total cells number and cell distributions in BAL fluid can provide an 
indication on the degree of pulmonary inflammation. There were large 
increases of total cell number in PEG-PTX 6k 50 mg/kg and 20k 20 
mg/kg groups at 24h, 72h, and 7 days. The total cell number in the 
Taxol group increased at 24h but decreased to normal level 72h post-
delivery (Fig. 20C). The group of PEG-PTX 6k at the low dose of 0.5 
mg/kg presented an increase of total cell number at 24h but less than 
the Taxol group. The group treated with only PEG-N3 6k at the 
corresponding dose of 50 mg/kg PTX had an increase of total cell 
number at 24h, but the number decreased to normal level at day 7. 
Cremophor EL also induced a large increase of total cell number in 
BAL at 24h.  
The number of neutrophils in BAL fluid is a cellular marker of 
inflammation. When PEG-PTX 6k was administered at the high dose 
of 50 mg/kg (PTX equiv.), the neutrophil number rose significantly to 
more than 10-fold that of the control group at 24h and 72h, and 
decreased to normal level at day 7 (Fig. 20E). In the groups of PEG-
PTX 20k and Taxol, increases of neutrophil numbers were found at 
24h and 72h, but neutrophil numbers were less than that of the PEG-
PTX 6k group at all time points tested. The influx of neutrophils 
contributed to the increase of total cell numbers in these three groups. 
When PEG-PTX 6k was given at a low dose of 0.5 mg/kg, there was 
no significant increase of neutrophil number. PEG-N3 6k 50 mg/kg 
(PTX equiv.) did not induce a significant increase of neutrophils at all 
time points tested. Cremophor EL given at the dose of 0.5 mg/kg (PTX 
equiv.) showed a significant increase of neutrophils numbers 24h post-
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delivery. In addition, foamy macrophages were found in the groups 
receiving PEG-PTX 6k, 20k at their MTD and PEG-N3 6k at 50 mg/kg 
(PTX equiv.) at all time points (Fig. 21).  
 
Fig. 21 Representative pictures showing foamy macrophages in (A) PEG-
PTX 20k group 7 days post-delivery and their absence in (B) PBS control 
group (colored by Diff Quick®, magnification × 40 under optical microscope). 
Generally, the histological examination showed no significant 
damages and changes in the structure and morphology of the lung 
parenchyma in all tested groups 24h post-delivery (Fig. 22). This was 
probably because obvious damages of lung parenchyma have not 
been induced yet. The group receiving PEG-PTX 6k at a low dose of 
0.5 mg/kg did not show obvious differences in morphology as 
compared with the PBS control group. There might be damages in the 
integrity of lung structure in some samples of Taxol 0.5 mg/kg group 
when compared with the control.  The thicknesses of bronchioles and 
alveolar epithelium appeared to be increased in groups treated with 
Taxol 0.5 mg/kg, PEG-PTX 6k 50 mg/kg (PTX equiv.), PEG-PTX 20k 
20mg/kg (PTX equiv.) and PEG-N3 6k 50 mg/kg (PTX equiv.), 
compared with the negative control. This might reflect an over-
production of mucus.       
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Fig. 22 Representative pictures showing lung morphology post intratracheal 
delivery of PBS control (A), Taxol 0.5 mg/kg (B), PEG-PTX 6k 50 mg/kg (C), PEG-
PTX 20k 20 mg/kg (D), PEG-PTX 0.5 mg/kg (E), and PEG-N3 50 mg/kg (F) 
(Hematoxylin-Eosin staining). 
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3.3 PEG-PTX conjugates increased anti-tumor efficacy in a 
murine model of lung carcinoma         
Both PEG-PTX 6k and 20k at their MTDs reduced the tumor cell 
number in the lungs compared to the non-treated control group (Fig. 
23). When comparing with Taxol i.t., PEG-PTX 6k and 20k also 
showed superior efficacy. Taxol delivered i.t. was not able to 
significantly reduce tumor cells in the lungs. There was no statistical 
difference between the groups of PEG-PTX 6k and 20k (Fig. 23B), 
which indicated that same anti-tumor efficacy could be achieved at a 
lower dose of paclitaxel with higher molecular weight of PEG. Taxol 
was also injected intravenously to compare the efficacy of different 
administration routes. However, intravenous Taxol at its MTD was not 
able to significantly decrease tumor cell number in the lungs. There 
was a slight and reversible body weight loss 1 and 2 days post-
intratracheal instillation in the conjugates and Taxol groups (Fig. 23C). 
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Fig. 23 Efficacy assessment of PEG-PTX conjugates and Taxol delivered by 
intratracheal instillation or intravenous injection in a murine model of Lewis 
lung carcinoma. (A) Representative images of mouse lungs. (B) Numbers of 
LL/2 tumor cells per milligram lung tissue. (C) Body weights of mice.  Mean 
± SEM are given, n=6-7.  * p < 0.05; NS, no significant difference (Mann-
Whitney). Similar results were obtained in two independent experiments. 
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3.4 PEG-PTX conjugates prolonged the retention time of 
paclitaxel in the lungs    
PEG-PTX 20k (20 mg/kg PTX equiv.) presented equivalent anti-
cancer efficacy and less local toxicity compared with PEG-PTX 6k at 
a 2.5 higher dose (50 mg/kg PTX equiv.). Therefore, we selected PEG-
PTX 20k to investigate the release of PTX from the conjugate in vivo 
and we used Taxol as a control. PEG-PTX 20k presented a prolonged 
release of PTX in both BAL and lungs (Fig. 24). Indeed, at 48h post-
delivery, PTX amount in BAL was still 40% of the dose recovered at 
time 0 (Fig. 24C). Most of the PTX released from the conjugate was 
present in the BAL at all time points, and only a small percentage was 
present in the lung tissue (Fig. 24C). In serum, the PTX released from 
conjugate was below limit of quantification at all time points. PEG-PTX 
20k showed a long retention time in both BAL and lungs. 43% and 20% 
of PEG-PTX 20k initial dose remained in BAL and lungs 48h post-
delivery, respectively (Fig. 24D). There was no PEG-PTX conjugate 
detected in serum at all time points. As a contrast, Taxol delivered at 
the dose of 0.5 mg/kg (10 µg of PTX per mouse) showed a quick 
clearance from the respiratory tract. Only 3.8 µg and 0.6 µg of PTX 
were present in BAL and lungs respectively at time 0 (Figs. 24A&B), 
but in serum the concentration of PTX was below the limit of 
quantification. PTX was also below the limit of quantification in serum, 
BAL and lungs 24h and 48h post-delivery.  
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Fig. 24 PTX and PEG-PTX 20k recovered from the respiratory tract 0h, 24h 
and 48h post intratracheal administration. (A) PTX amount in BAL and (B) 
PTX amount in the lungs in mice having received PEG-PTX 20k (20 mg/kg 
PTX equiv.) and Taxol (0.5 mg/kg). (C) Amount of PTX expressed as a 
percentage of the total dose recovered from BAL, lungs and serum at time 
0. (D) Amount of PEG-PTX 20k expressed as a percentage of the total dose 
recovered from BAL and lungs at time 0. * p<0.05, when compared with Taxol 
group (Mann-Whitney); BQ, below quantification limit.  
4. Discussion  
The present study demonstrated that PEG-PTX conjugates had lower 
toxicity but superior anti-tumor efficacy than Taxol when administered 
i.t. to mice. We used PEGylation to solubilize PTX instead of 
Cremophor EL, which reduced the local toxicity. Moreover, the choice 
of large MW of PEG (20 kDa) prolonged the retention time of paclitaxel 
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in the lungs, which led to the improved efficacy. These results 
suggested that PEGylation of chemotherapeutics could be an effective 
approach to embody inhaled chemotherapy in the future.  
Conjugation of PTX to PEG largely increased the MTD following 
intratracheal instillation. The MTD of PEG-PTX 6k i.t. was 100-fold of 
Taxol i.t.. This could be attributed to the prodrug nature of PEG-PTX 
conjugates. Intratracheal delivery of PEG-PTX 6k at a high dose (50 
mg/kg PTX equiv.) increased LDH and neutrophils levels in BAL 24h 
post-delivery. However, delivery of equiv. dose of PEG-N3 6k did not 
increase LDH and neutrophils significantly. Therefore, the toxicity of 
conjugates mainly came from the high dose of PTX itself.  Taxol 
containing 50% of Cremophor EL was used as the PTX control in this 
study. Intratracheal delivery of either Taxol or Cremophor EL alone 
caused increased levels of LDH and neutrophils, which indicated that 
the pulmonary toxicity was induced by both PTX and the Cremophor 
EL. Although it is not suitable for pulmonary delivery, Cremophor EL is 
needed in the formulation to solubilize the desired amount of PTX. 
Further, PEG-PTX 6k delivered at the same low dose as Taxol (0.5 
mg/kg PTX equiv.) did not induce significant toxicity to the lungs. 
These results suggested that PEGylation reduced the local toxicity of 
the native drug and that the local toxicity of PEG-PTX conjugates was 
dose-dependent.  
As PEG-PTX 20k presented long retention time in the lungs, 
toxicological concerns may arise from long-term accumulation of high 
molecular weight PEG in the lungs. The safety of PEG 3,350 Da has 
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been proved in rats following 2-week exposure by aerosol (140). 
However, there is no safety study on large PEG (> 5 kDa) delivered by 
inhalation. In this study, PEG-N3 6k at 200 mg/kg (50 mg/kg PTX equiv.; 
5 mg of PEG-N3 6k per mouse) presented acceptable safety over 7 
days following a single administration dose in the lungs. Generally, 
PEG is non-toxic and extensively used in drug delivery. It has been 
approved for human use in intravenous, oral and pulmonary 
formulations. However, the non-biodegradable property of PEG might 
be the drawback for application by inhalation. It is anticipated that 
either PEG-PTX or the free PEG released following the hydrolysis of 
PEG-PTX would be partially cleared by mucociliary clearance and by 
alveolar macrophages. The fraction absorbed in the systemic 
circulation would likely be eliminated by renal clearance (141). 
Considering the large PEG size and the high doses delivered, long-
term safety studies are needed to ascertain the safety of inhaled PEG-
PTX.  
43% and 20% of the PEG-PTX 20k initial dose were still present in 
BAL and lungs 48h post-intratracheal instillation, respectively. In 
previous studies of PEG retention in the lungs, PEG with MW > 5 kDa 
was not quickly cleared and absorbed into the systemic circulation (46). 
In addition, 60% of the initial dose of PEG 40 kDa remained in murine 
lungs 48h post-intratracheal instillation (87). Therefore, the prolonged 
retention of PEG-PTX 20k was probably due to the large MW of PEG.  
As compared with other drug delivery systems, PEG-PTX showed 
increased retention time of the drug in the lungs. Koshkina et al. 
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investigated the delivery of liposomal PTX by aerosol inhalation (63). 
PTX was released and reached the concentration peak in the lungs 
after 30 min of inhalation but it was cleared within 3 hours. Gill et al. 
studied the administration of PTX micelles by the pulmonary route (65). 
This system showed prolonged drug retention of PTX in the lungs 
compared to Taxol® administrated intratracheally. Paclitaxel 
concentration at 12h post-delivery was found to be 46% of that at 1h 
post-delivery. Kaminskas et al. assessed the pulmonary delivery of a 
PEGylated polylysine dendrimer of doxorubicin (133). They 
demonstrated that 20% of the initial dose of the doxorubicin dendrimer 
was present in the BAL and the lungs 1 day after the intratracheal 
instillation, respectively.  
It is anticipated that the slightly acidic microenvironment of the tumor 
would lead to accelerated cleavage of PTX from the conjugate 
backbone compared with the non-tumor area (142, 143). Therefore, 
the hydrolysis of PEG-PTX could possibly take place prior to the 
internalization of the conjugates, which possibly resulted in a high 
proportion of PTX in the interstitial tumor area within the lungs (Fig. 
25). On the other hand, there are also opportunities for conjugates to 
be taken up by the cells via endocytosis, leading to the drug release 
in cytoplasm. It is likely that the PTX concentrations achieved using 
PEG-PTX was high enough to improve lung tumor exposure to PTX, 
because PEG-PTX showed significantly increased tumor regression 
compared with the intravenously or intratracheally injected Taxol.  
The intratracheal delivery of PEGT-PTX 6k and 20k conjugates 
demonstrated superior anti-tumor efficacy than both i.v. and i.t. 
CHAPTER 3. PEGYLATION OF PACLITAXEL LARGELY IMPROVES ITS SAFETY AND 
ANTI-TUMOR EFFICACY FOLLOWING PULMONARY DELIVERY IN A MOUSE MODEL 
OF LUNG CARCINOMA 
 
  102 
 
administered Taxol, the formulation of the free drug. This result 
suggests that both the local delivery and the PEGylation of PTX 
contributed to the enhanced efficacy. As discussed above, PEG-PTX 
also demonstrated lower local toxicity than Taxol. Therefore, our 
hypothesis that PEGylation can improve the anti-tumor efficacy with 
reduced local toxicity is demonstrated. Moreover, since PEG-PTX 20k 
at a lower dose than PEG-PTX 6k showed equivalent anti-tumor 
efficacy but less toxicity, it could be assumed that better efficacy and 
lower toxicity could be achieved with higher molecular weight of PEG.  
As a summary, PEGylated PTX can increase anti-tumor efficacy 
compared to Taxol post i.t. delivery. PEGylated paclitaxel can also 
greatly improve the MTD i.t. and decrease local toxicity. The retention 
time of PTX can be prolonged by conjugation to PEG with large MW. 
Therefore, PEG-PTX conjugates are a promising system for 
application in inhaled chemotherapy.   
 
Fig. 25 Illustration of possible release mechanism of PTX from conjugates in 
the lungs.
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1. Main achievements 
1.1 Outcomes of the thesis 
Inhaled chemotherapy can be an alternative to systemic 
chemotherapy. However, administration of chemotherapeutics directly 
to the lungs will lead to local toxicity. In addition, the fast clearance 
mechanisms of the lungs will result in short retention time of anti-
cancer drugs in the lungs. These impediments limit the therapeutic 
efficacy of inhaled chemotherapeutics. The aim of this thesis was to 
use polymer-drug conjugates to reduce the local toxicity and prolong 
the retention time of chemotherapeutics in the lungs. The improved 
anti-cancer efficacy can be achieved by the local retention and 
sustained release of the chemotherapeutics.  
The first part of the thesis focused on the design and synthesis of 
PEG-PTX conjugates. PTX was conjugated to PEG 6 kDa and 20 kDa 
by ester bonds in two structures: 1) PEG-N3-PTX, via “click” chemistry; 
2) PEG-suc-PTX, with a succinic spacer between PEG and PTX.  
The conjugates were produced and purified at an acceptable yield of 
70%. The drug loading reached 20% and 7% (w/w) in all the structures 
of 6 kDa and 20 kDa conjugates, respectively. The molecular ratio of 
PTX in PEG-PTX conjugates was approximately 1.8 PTX per PEG 
molecule in both structures and both molecular weights. All the 
conjugates largely improved the solubility of PTX by 3-4 orders of 
magnitude.  
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In a second step, we evaluated the stability and toxicity of PEG-PTX 
conjugates in vitro. The conjugates showed very good stability in PBS 
pH 6.9 (pH of lung lining fluid) with half-lives longer than 72 hours. The 
conjugates also presented good stability in BAL with half-lives 
between 3 to 9 hours. The PEG-N3-PTX conjugates were more stable 
than the PEG-suc-PTX conjugates. To test the cytotoxicity of these 
conjugates, the conjugates were incubated with two cancer cell lines. 
These conjugates were cytotoxic, but less than Taxol, the commercial 
product of paclitaxel. All these in vitro results indicated that PEGylation 
of PTX has the potential to prolong the retention of PTX in the lungs 
and reduce local toxicity. PEG-N3-PTX conjugates were chosen for the 
in vivo evaluation because of their increased stability.  
We were then interested to evaluate whether PEGylation could reduce 
the toxicity of PTX. Maximum tolerated doses were determined 
following intratracheal delivery of PEG-PTX to healthy mice. Results 
showed PEGylation can improve the MTD of PTX by up to 100 fold. 
To investigate the local toxicity of PEG-PTX conjugates, several 
inflammation markers including total protein, lactate dehydrogenase, 
and cell components were examined in the lungs following 
intratracheal delivery of PEG-PTX conjugates. PEG-PTX conjugates 
at high doses (MTDs) induced local toxicity, but at a lower dose, the 
toxicity was largely reduced to an acceptable level. This was due to 
the prodrug nature of the PEG-PTX conjugates which could avoid the 
transient high concentration of chemotherapeutics in the lungs.   
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Based on the MTD of conjugates, the anti-tumor efficacy was 
evaluated in a mouse model of Lewis lung carcinoma. We compared 
the efficacy of PEGylated PTX at different molecular weights with 
native PTX following intratracheal or intravenous delivery. Both PEG-
PTX 6k and 20k demonstrated superior efficacy compared with Taxol 
delivered either intratracheally or intravenously. Therefore, PEGylation 
is an effective method to improve anticancer efficacy of inhaled 
chemotherapeutics. 
To further understand the impact of PEGylation on the residence time 
of PTX, in vivo release of PTX from the conjugates were evaluated. 
PEGylated PTX appeared to significantly prolong its residence time in 
the lungs compared to the non-PEGylated free drug. The large 20 kDa 
PEG contributed greatly in the improving the residence time of the 
conjugate.  
To the best of our knowledge, this is the first study about PEGylation 
of chemotherapeutics for pulmonary delivery in lung cancer. The main 
contributions of thesis are the improvement of the anti-cancer efficacy 
and the large reduction of toxicity of inhaled chemotherapeutics by 
PEGylation.  
1.2 Synthesis of PEG-conjugated paclitaxel with cleavable 
linkage for pulmonary application 
Initially, we use the strategy of adding an amino acid spacer between 
PEG and PTX. N, N′-disuccinimidyl carbonate (DSC) was used to 
activate PEG and then the activated PEG-DSC was supposed to react 
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with glycine. However, the method was not successful mainly due to 
the low yield and low substitution rate of PTX on PEG terminals. 
Therefore, this method was not pursued. 
Afterwards, we performed “click” chemistry to conjugate alkyne 
modified PTX to azide activated PEG. Thanks to this efficient reaction, 
a high yield of PEG-N3-PTX conjugates were obtained with high 
substitution rate. The structure of the PEG-N3-PTX conjugate is novel 
with a hydrolysable ester bond and a stable triazole link between PEG 
and PTX. The ester bond ensures that paclitaxel can be released in 
an intact form and the triazole link enhances the stability of the 
conjugate. Although various polymer-paclitaxel conjugates have been 
prepared, few studies have been performed in the field of pulmonary 
drug delivery. To the best of our knowledge, this study is the first to 
report PEGylation of PTX using “click” chemistry in pulmonary delivery. 
In the case of the pulmonary delivery of chemotherapeutics, sustained 
local drug concentrations are crucial to achieve anti-tumor efficacy. 
Therefore, a long residence time of the conjugates in the lungs is 
necessary. Herein, high molecular weight PEG (6 kDa and 20 kDa) 
were used with the expectation of long drug residency in the lungs (46). 
Then, because of the hydrolysable ester bonds between PEG and 
PTX, PTX will be released progressively to take anti-tumor effect.  
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1.3 Increased anti-tumor efficacy and prolonged lung retention of 
chemotherapeutics 
The PEGylated PTX 6k and 20k delivered intratracheally 
demonstrated superior anti-tumor efficacy than the free drug 
formulation Taxol when delivered both intratracheally and 
intravenously. The results indicated pulmonary delivery increased 
accumulation of PEG-PTX conjugates just in the lungs, which resulted 
in the relatively higher drug concentration in tumors than that of the 
intravenously administered Taxol. Moreover, PEGylation played a very 
important role in the achievement of improved anti-tumor efficacy. 
These results were consistent with our hypothesis that PEGylation 
offers the sustained release of PTX, which enables the single high 
dose treatment to demonstrate prolonged the anti-tumor efficacy with 
low toxicity. In the literature, previously work of polyglutamic acid 
paclitaxel conjugate (PGA-PTX) delivered intratracheally showed 
better anti-tumor efficacy than Taxol but with reduced toxicity (111, 112, 
144, 145). This promising result was also a proof of concept that 
polymer drug conjugates would be a reasonable strategy for inhaled 
chemotherapy.  
43 % and 20% of the initial dose of the PEG-PTX 20k conjugate 
remained in BAL and lung tissue 48h post-delivery, respectively. This 
prolonged effect was probably due to the large MW of PEG. As PEG 
with MW > 5 kDa could not be cleared and absorbed into systemic 
circulation quickly (46), it offered the opportunity for the drug 
conjugated to have a long retention time. Moreover, since PEG-PTX 
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20k at a lower dose showed equivalent anti-tumor efficacy as PEG-
PTX 6k, it could be assumed that higher molecular weight of PEG 
would demonstrate longer retention in the lungs, thus better anti-tumor 
efficacy could be achieved. As compared with other delivery systems 
such as liposome, micelle and dendrimer of chemotherapeutics, PEG-
PTX showed longer retention time of drug in the lungs (63, 65, 133). 
This indicated that PEGylation with large PEG is a very effective 
method to achieve sustained release of anti-cancer drug in the lungs  
1.4 Improved MTD and reduced local toxicity for inhaled 
chemotherapy 
Delivery of native chemotherapeutics would lead to unexpected acute 
local toxicity in the lungs. A study of inhalation solutions of doxorubicin 
(dissolved in 20% ethanol) in pet dogs with spontaneously occurred 
lung cancer showed pneumonitis and fibrosis (33). In our study, 
administration of both 6k and 20k PEG-PTX at MTD increased LDH 
level and neutrophil number, though these markers could return to 
normal levels after 7 days. As the dose decreased to 0.5 mg/kg (PTX 
equiv.) of PEG-PTX 6k, no inflammation was found. The intratracheal 
delivery of only PEG-N3 6k did not induce the rise of inflammatory 
markers, which indicated the toxicity was a result of high dose of PTX 
(50 mg/kg PTX equiv.). Although there was still inflammation, 
PEGylation of PTX improved the MTD by up to 100-fold compared with 
Taxol. PTX could be delivered at high doses in a tolerated manner. As 
the sustained release feature of PEG-PTX, the treatment could be 
given with reduced frequency. Therefore, the overall toxicity of PEG-
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PTX was much lower than the native PTX formulation. The local 
bioavailability was improved.  
1.5 Summary 
The present thesis demonstrates that PEGylation of 
chemotherapeutics with large PEG enhances the anti-tumor efficacy 
and reduces the local toxicity after administration to the respiratory 
tract. Further, it shows that PEGylation prolongs the residence time of 
chemotherapeutics in the lungs.  
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2. Perspectives 
2.1 Long-term toxicity 
In this study, we evaluated the acute and local toxicity of PEGylated 
PTX. PEG-PTX largely improved the MTD of PTX following 
intratracheal delivery. Inflammation was found at the high doses of 
PEG-PTX (50 and 20 mg/kg PTX equiv.), which have significant anti-
tumor efficacy. We followed the toxicity of inhaled PEG-PTX at MTD 
for 7 days with a single dose treatment. The results showed 
acceptable toxicity. Given that repeated doses and relatively long term 
treatments are usually needed in chemotherapy, the chronic toxicity of 
inhaled PEG-PTX is noteworthy to investigate. More precisely, the 
long-term tolerability of the lungs to repeated doses of the PEGylated 
PTX versus the unconjugated free drug should be evaluated by 
examining biochemical and cellular components in broncho-alveolar 
lavage in extended time periods, for instance 1 to 3 months. Further, 
it would be interesting to investigate the local toxic effect of different 
sizes of PEG-PTX to provide further understanding of inhalable 
PEGylated chemotherapeutics.    
Generally, PEG is considered to be devoid of toxicity except at high 
parenteral doses where renal failure has been observed (146). Klonne 
et al. studied the toxicity of 3.4 kDa PEG at a daily dose of 1.8 g/m3 
delivered by inhalation for 2 weeks, and found little toxicity in rat lungs 
(140). No toxicity study on large PEG (> 5 kDa) in the lungs was found 
in the literature. Large PEGs were found to have long retention times 
in the lungs (46, 87). The fact that large PEG could remain for long 
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times within the lungs generates concerns of long-term safety, thus the 
importance to investigate the chronic toxicology of PEG-PTX cannot 
be neglected.  
2.2 Improvement of polymer-drug conjugation strategy 
We used linear PEG 6 kDa and 20 kDa for the PEGylation of PTX in 
this study, which provided drug loading percentages of 20% and 7%, 
respectively. However, the drug loading percentage could be further 
improved by using multi-branched PEG. The branched PEG will 
provide more reactive terminal hydroxyl for PEGylation, which could 
increase the drug molecules on each PEG. With increased drug 
content in the conjugate, less PEG will be delivered to the lungs. For 
instance, PEGylated docetaxel (NKTR-105) now in clinical trial was 
produced with multi-arm PEG (84). Obstacles may be the 
characterization and detection of these branched conjugates in vitro 
and in vivo. Radio labeling could be an option to follow the fate of these 
conjugates in vivo as this technology has been used in one study of 
doxorubicin dendrimer (133).  
To further explore the pulmonary application of polymer-drug 
conjugates, other biodegradable polymers can also be considered to 
replace PEG. The most commonly used natural polymers are 
polysaccharides, chitosan, gelatin and hyaluronic acid. In addition, 
some synthetic biodegradable polymers such as poly lactic acid (PLA), 
poly vinyl alcohol (PVA), and poly lactic glycolic acid (PLGA) can also 
be options to synthesize polymer-drug conjugates (147). By choosing 
appropriate molecular weight and structure, long retention time as well 
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as reduced toxicity of chemotherapeutics could be achieved. As the 
polymers are biodegradable, the safety concerns of elimination would 
be minimized as compared with PEG.  
2.3 Mechanisms involved in the lung retention of PEGylated 
paclitaxel   
In this study, we hypothesized that PEG-PTX conjugates presented 
long retention time in the lungs because of the large molecular weight 
of PEG. It would be essential to further investigate the parameters that 
influence the retention of PEGylated PTX.  
PEG molecular weight. In this work, Kinetics of in vivo distribution of 
PEG-PTX conjugates in the respiratory tract showed that 43% of 
initially dosed PEG-PTX 20k stayed in murine lungs 48h post-delivery. 
Moreover, Koussoroplis et al. found that 60 % of initial dosed PEG 40 
kDa stays in murine lungs 48h post-delivery. One study about retention 
of dendrimers in the lungs showed that approximately 20−30% of the 
dose of relatively small (<22 kDa) dendrimers were systemically 
absorbed compared to only 2% absorption for a larger (78 kDa) 
PEGylated dendrimer 48h post-delivery (148). These data suggested 
that the retention time of polymer in the lungs is highly related to the 
molecular weight. In addition, mucoadhesion might be one reason that 
large PEG would possess long retention time in the lungs. However, 
the mucoadhensive effect might be more significant with large (> 20 
kDa) PEG. Above all, it would be interesting to varying polymer size to 
observe the relation between retention time and polymer size in 
murine lungs. The retention time of unconjugated PEG should also be 
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investigated.  
Administration site. Conjugates can be delivered using different 
techniques to reach specific regions of the respiratory tract. Different 
administration sites may result in different depositing position of the 
conjugates in the respiratory tract. As the rate of mucociliary clearance 
decreases from the proximal to the distal lungs, the deposition sites of 
the conjugates might have influence on the retention time. If the 
conjugates are delivered to the deep lungs, the retention time is 
assumed to be prolonged. Nasal lavage, bronchoalveolar lavage and 
lung tissues could be collected post-administration of the conjugates 
and the concentration of PEG-PTX could be analyzed to study the 
retention time.  
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